Veradigm (MDRX) 10-Q 7 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	0001124804
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		109,259,776
Entity File Number	001-35547
Entity Tax Identification Number	36-4392754
Entity Address, Address Line One	222 Merchandise Mart
Entity Address, Address Line Two	Suite 2024
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	800
Local Phone Number	334-8534
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 492,597	$ 132,517
Restricted cash	1,307	1,308
Accounts receivable, net of allowance of $12,868 and $13,360 as of September 30, 2022 and December 31, 2021, respectively	169,029	171,622
Contract assets, net of allowance of $564 and $576 as of September 30, 2022 and December 31, 2021, respectively	65,453	63,429
Prepaid expenses and other current assets	74,384	60,511
Assets held for sale	8,000	331,955
Total current assets attributable to discontinued operations	810,770	761,342
Fixed assets, net	11,713	9,819
Software development costs, net	78,103	74,688
Intangible assets, net	145,255	149,690
Goodwill	523,927	506,607
Deferred taxes, net	6	0
Contract assets - long-term, net of allowance of $1,201 and $1,534 as of September 30, 2022 and December 31, 2021, respectively	27,957	28,174
Right-of-use assets - operating leases	14,520	18,324
Other assets	78,408	83,429
Long-term assets attributable to discontinued operations	0	793,156
Total assets	1,690,659	2,425,229
Current liabilities:
Accounts payable	12,609	5,281
Accrued expenses	82,917	54,518
Accrued compensation and benefits	33,857	31,055
Deferred revenue	98,930	120,748
Current operating lease liabilities	6,166	6,133
Current liabilities attributable to discontinued operations	18,612	329,347
Total current liabilities attributable to discontinued operations	253,091	547,082
Long-term debt	200,326	350,062
Deferred revenue	3,060	1,839
Deferred taxes, net	8,082	16,625
Long-term operating lease liabilities	12,315	16,754
Other liabilities	36,762	33,823
Long-term liabilities attributable to discontinued operations	0	50,906
Total liabilities	513,636	1,017,091
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2022 and December 31, 2021; 279,600 and 109,260 shares issued and outstanding as of September 30, 2022, respectively; 276,705 and 116,114 shares issued and outstanding as of December 31, 2021, respectively	2,794	2,766
Treasury stock: at cost, 170,340 and 160,591 shares as of September 30, 2022 and December 31, 2021, respectively	(1,498,836)	(1,321,805)
Additional paid-in capital	1,923,559	1,962,386
Retained earnings	753,392	767,556
Accumulated other comprehensive loss	(3,886)	(2,765)
Total stockholders’ equity	1,177,023	1,408,138
Total liabilities and stockholders’ equity	$ 1,690,659	$ 2,425,229

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 12,868	$ 13,360
Contract assets, allowance	564	576
Total contract assets, long-term	$ 1,201	$ 1,534
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	279,600,000	276,705,000
Common stock, shares outstanding	109,260,000	116,114,000
Treasury stock at cost, shares	170,340,000	160,591,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Revenue from contract with customers	$ 151,922	$ 144,668	$ 445,492	$ 419,526
Cost of revenue:
Total cost of revenue	68,486	75,028	209,093	218,550
Gross profit	83,436	69,640	236,399	200,976
Selling, general and administrative expenses	32,518	27,392	133,683	87,680
Research and development	23,681	21,042	69,851	62,644
Asset impairment charges	0	359	0	531
Amortization of intangible and acquisition-related assets	2,236	2,363	6,648	7,090
Income from operations	25,001	18,484	26,217	43,031
Interest expense	(1,246)	(3,617)	(5,269)	(9,709)
Other income, net	1,655	4,493	3,800	21,819
Gain on sale of businesses, net	0	8,363	0	8,363
Equity in net loss income of unconsolidated investments	(617)	(257)	(1,222)	(321)
Income from continuing operations before income taxes	24,793	27,466	23,526	63,183
Income tax (provision) benefit	(13,868)	(7,190)	9,132	(12,464)
Income from continuing operations, net of tax	10,925	20,276	32,658	50,719
Income (loss) from discontinued operations	(434)	(6,187)	(9,252)	(6,545)
Gain on sale of discontinued operations	5,174	0	7,939	647
Income tax effect on discontinued operations	(1,137)	2,091	(57,986)	2,342
Income (loss) from discontinued operations, net of tax	3,603	(4,096)	(59,299)	(3,556)
Net income (loss)	$ 14,528	$ 16,180	$ (26,641)	$ 47,163
Basic
Continuing operations	$ 0.10	$ 0.16	$ 0.29	$ 0.38
Discontinued operations	0.03	(0.03)	(0.52)	(0.03)
Net earnings (loss) per Common Share	0.13	0.13	(0.23)	0.35
Diluted
Continuing operations	0.09	0.15	0.25	0.36
Discontinued operations	0.03	(0.03)	(0.44)	(0.03)
Net earnings (loss) per Common Share	$ 0.12	$ 0.12	$ (0.19)	$ 0.33
Provider [Member]
Revenue:
Revenue from contract with customers	$ 122,811	$ 118,179	$ 360,415	$ 345,253
Cost of revenue:
Total cost of revenue	57,252	61,606	172,595	180,566
Payer & Life Sciences [Member]
Revenue:
Revenue from contract with customers	29,111	26,489	85,077	74,273
Cost of revenue:
Total cost of revenue	$ 11,234	$ 13,422	$ 36,498	$ 37,984

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ 14,528	$ 16,180	$ (26,641)	$ 47,163
Other comprehensive income (loss):
Foreign currency translation adjustments	59	(805)	(808)	(285)
Change in fair value of derivatives qualifying as cash flow hedges	(16)	0	(420)	(1,509)
Other comprehensive income (loss) before income tax benefit	43	(805)	(1,228)	(1,794)
Income tax benefit related to items in other comprehensive income (loss)	5	0	107	390
Total other comprehensive income (loss)	48	(805)	(1,121)	(1,404)
Comprehensive income	$ 14,576	$ 15,375	$ (27,762)	$ 45,759

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Cumulative Effect Period Of Adoption Adjustment [Member] Revision Of Prior Period Accounting Standards Update Adjustment [Member]	Retained Earnings (Accumulated Deficit) [Member]	Retained Earnings (Accumulated Deficit) [Member] Cumulative Effect Period Of Adoption Adjustment [Member] Revision Of Prior Period Accounting Standards Update Adjustment [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance, Shares at Dec. 31, 2020		274,558,000	(134,616,000)
Beginning Balance at Dec. 31, 2020	$ 1,666,243	$ 2,745	$ (870,558)	$ 1,902,776		$ 633,118		$ (1,838)
Beginning Balance (ASU 2020-06 [Member]) at Dec. 31, 2020					$ 0		$ 0
Stock-based compensation				25,861
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		2,139,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 21		(13,988)
Issuance of treasury stock, Shares			33,000
Issuance of treasury stock	534		$ 465	69
Purchase of treasury stock, Shares			(6,397,000)
Purchase of treasury stock			$ (108,953)
Accelerated share repurchase program, Shares			(13,146,000)
Accelerated share repurchase program			$ (234,269)	34,269
Warrants issued				3,110
Net income (loss)						47,163
Foreign currency translation adjustments, net	285							(285)
Unrecognized loss on derivatives qualifying as cash flow hedges, net of tax								(1,119)
Ending Balance, Shares at Sep. 30, 2021		276,697,000	(154,126,000)
Ending Balance at Sep. 30, 2021	1,418,587	$ 2,766	$ (1,213,315)	1,952,097		680,281		(3,242)
Ending Balance (ASU 2020-06 [Member]) at Sep. 30, 2021							0
Beginning Balance, Shares at Dec. 31, 2020		274,558,000	(134,616,000)
Beginning Balance at Dec. 31, 2020	$ 1,666,243	$ 2,745	$ (870,558)	1,902,776		633,118		(1,838)
Beginning Balance (ASU 2020-06 [Member]) at Dec. 31, 2020					0		0
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	2,200,000
Ending Balance, Shares at Dec. 31, 2021	276,705,000	276,705,000	(160,591,000)
Ending Balance at Dec. 31, 2021	$ 1,408,138	$ 2,766	$ (1,321,805)	1,962,386		767,556		(2,765)
Ending Balance (ASU 2020-06 [Member]) at Dec. 31, 2021					(38,918)		12,477
Beginning Balance, Shares at Jun. 30, 2021		276,668,000	(151,657,000)
Beginning Balance at Jun. 30, 2021	1,393,474	$ 2,766	$ (1,174,498)	1,903,542		664,101		(2,437)
Beginning Balance (ASU 2020-06 [Member]) at Jun. 30, 2021					0
Stock-based compensation				8,777
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		29,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 0		(76)
Issuance of treasury stock, Shares			0
Issuance of treasury stock			$ 0	0
Purchase of treasury stock, Shares			0
Purchase of treasury stock			$ 0
Accelerated share repurchase program, Shares			(2,469,000)
Accelerated share repurchase program			$ (38,817)	38,817
Warrants issued				1,037
Net income (loss)						16,180
Foreign currency translation adjustments, net	(805)							(805)
Unrecognized loss on derivatives qualifying as cash flow hedges, net of tax								0
Ending Balance, Shares at Sep. 30, 2021		276,697,000	(154,126,000)
Ending Balance at Sep. 30, 2021	$ 1,418,587	$ 2,766	$ (1,213,315)	1,952,097		680,281		(3,242)
Ending Balance (ASU 2020-06 [Member]) at Sep. 30, 2021							0
Beginning Balance, Shares at Dec. 31, 2021	276,705,000	276,705,000	(160,591,000)
Beginning Balance at Dec. 31, 2021	$ 1,408,138	$ 2,766	$ (1,321,805)	1,962,386		767,556		(2,765)
Beginning Balance (ASU 2020-06 [Member]) at Dec. 31, 2021					(38,918)		12,477
Stock-based compensation				24,503
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	2,900,000	2,895,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 28		(32,707)
Issuance of treasury stock, Shares			0
Issuance of treasury stock	$ 0		$ 0	0
Purchase of treasury stock, Shares			(9,749,000)
Purchase of treasury stock			$ (177,031)
Accelerated share repurchase program, Shares			0
Accelerated share repurchase program			$ 0	0
Warrants issued				8,295
Net income (loss)						(26,641)
Accounting Standards Update [Extensible List]	Stock-based compensation
Foreign currency translation adjustments, net	$ (808)							(808)
Unrecognized loss on derivatives qualifying as cash flow hedges, net of tax								(313)
Ending Balance, Shares at Sep. 30, 2022	279,600,000	279,600,000	(170,340,000)
Ending Balance at Sep. 30, 2022	$ 1,177,023	$ 2,794	$ (1,498,836)	1,923,559		753,392		(3,886)
Beginning Balance, Shares at Jun. 30, 2022		279,175,000	(168,383,000)
Beginning Balance at Jun. 30, 2022	1,196,348	$ 2,790	$ (1,465,177)	1,923,805		738,864		(3,934)
Beginning Balance (ASU 2020-06 [Member]) at Jun. 30, 2022					$ 0		$ 0
Stock-based compensation				4,553
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		425,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 4		(4,799)
Issuance of treasury stock, Shares			0
Issuance of treasury stock			$ 0	0
Purchase of treasury stock, Shares			(1,957,000)
Purchase of treasury stock			$ (33,659)
Accelerated share repurchase program, Shares			0
Accelerated share repurchase program			$ 0	0
Warrants issued				0
Net income (loss)						14,528
Foreign currency translation adjustments, net	$ 59							59
Unrecognized loss on derivatives qualifying as cash flow hedges, net of tax								(11)
Ending Balance, Shares at Sep. 30, 2022	279,600,000	279,600,000	(170,340,000)
Ending Balance at Sep. 30, 2022	$ 1,177,023	$ 2,794	$ (1,498,836)	$ 1,923,559		$ 753,392		$ (3,886)

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)	Sep. 30, 2022	Jun. 30, 2022	Jun. 30, 2020	Dec. 31, 2019
0.875% Convertible Senior Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	0.875%	0.875%	0.875%	0.875%

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net (loss) income	$ 14,528	$ 16,180	$ (26,641)	$ 47,163
Less: Loss from discontinued operations	3,603	(4,096)	(59,299)	(3,556)
Income from continuing operations	10,925	20,276	32,658	50,719
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization			42,278	49,042
Non-cash lease expense, net			(5,289)	(8,822)
Stock-based compensation expense			19,901	8,804
Deferred taxes			(2,978)	4,468
Impairment of assets and long-term investments			0	531
Equity in net loss of unconsolidated investments	617	257	1,222	321
Gain on sale of businesses, net	0	(8,363)	0	(8,363)
Other income, net			(1,208)	(4,292)
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net			72,287	(18,212)
Prepaid expenses and other assets			29,698	(4,532)
Accounts payable			21,022	(2,628)
Accrued expenses			1,054	42,129
Accrued compensation and benefits			(1,921)	(10,325)
Deferred revenue			(68,065)	(4,823)
Other liabilities			(21,658)	4,528
Net cash provided by operating activities - continuing operations			119,001	98,545
Net cash used in operating activities - discontinued operations			(23,234)	(239,018)
Net cash provided by (used in) operating activities			95,767	(140,473)
Cash flows from investing activities:
Capital expenditures			(1,876)	(1,050)
Capitalized software			(26,207)	(26,595)
Cash paid for business acquisitions, net of cash acquired			(24,106)	0
Sale of businesses and other investments, net of cash divested, and distributions received			672,498	5,380
Purchases of equity securities, other investments and related intangible assets, net			(1,342)	(219)
Net cash provided by (used in) investing activities - continuing operations			618,967	(22,484)
Net cash used in investing activities - discontinued operations			(15,248)	(32,388)
Net cash provided by (used in) investing activities			603,719	(54,872)
Cash flows from financing activities:
Taxes paid related to net share settlement of equity awards			(32,666)	(12,718)
Credit facility payments			(200,000)	(50,000)
Credit facility borrowings, net of issuance costs			22,335	250,000
Repurchase of common stock			(177,031)	(308,953)
Intercompany to/from parent/subsidiaries			11,685	47,323
Payment of acquisition and other financing obligations			0	(2,400)
Net cash used in financing activities - continuing operations			(375,677)	(76,748)
Net cash used in financing activities - discontinued operations			(11,697)	(48,572)
Net cash used in financing activities			(387,374)	(125,320)
Effect of exchange rate changes on cash and cash equivalents			(728)	(480)
Net increase (decrease) in cash and cash equivalents			311,384	(321,145)
Cash, cash equivalents and restricted cash, beginning of period			190,520	537,465	$ 537,465
Cash, cash equivalents and restricted cash, end of period	501,904	216,320	501,904	216,320	$ 190,520
Less: Cash and cash equivalents attributable to discontinued operations	(8,000)	(72,680)	(8,000)	(72,680)
Cash, cash equivalents and restricted cash, end of period, excluding discontinued operations	$ 493,904	$ 143,640	$ 493,904	$ 143,640

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year ending December 31, 2022. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the current economic conditions, including macroeconomic and inflationary trends, and the economic impact of the COVID-19 pandemic, on our critical and significant accounting estimates. Actual results could differ materially from these estimates. Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The amendments in ASU 2020-06 simplify the accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also requires the application of the if-converted method for calculating diluted earnings per share, whereas the treasury stock method is no longer permitted for convertible instruments. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition, which resulted in an increase in long-term debt of $ 26.4 million, a decrease in additional paid-in capital of $ 38.9 million and an increase to retained earnings of $ 12.5 million, as of January 1, 2022. Refer to Note 10, “Debt” for additional information. Accounting Pronouncements Not Yet Adopted In October 2021, the FASB issued Accounting Standards Update No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”), which requires contract assets and contract liabilities (deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification (“ASC”) 606, “ Revenue from Contracts with Customers” , as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, “ Business Combinations” . The new standard should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The standard is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the effects of the adoption of ASU 2021-08 on our consolidated financial statements. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	2. Revenue from Contracts with Customers Our two primary revenue streams are (i) provider revenue and (ii) payer and life sciences revenue. Provider revenue consists of revenue derived from software applications for patient engagement and the sale of EHR software to single-specialty and small and mid-sized physician practices, including related clinical, financial, administrative and operational solutions. Payer and life sciences revenue primarily consists of sales of our integrated data systems solutions and related services to key healthcare stakeholders, including health plans and pharmaceutical companies, to help them improve the quality, efficiency and value of healthcare delivery. At September 30, 2022 and December 31, 2021, we had capitalized costs to obtain or fulfill a contract of $ 9.4 million and $ 8.1 million, respectively, in Prepaid and other current assets and $ 10.6 million and $ 11.9 million, respectively, in Other assets. During the three months ended September 30, 2022 and 2021, we recognized $ 3.0 million and $ 3.1 million, respectively, of amortization expense related to such capitalized costs. During the nine months ended September 30, 2022 and 2021, we recognized $ 8.8 million and $ 9.3 million, respectively, of amortization expense related to such capitalized costs. The amortization of these capitalized costs to obtain a contract are included in Selling, general and administrative expense within our consolidated statements of operations. The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivable, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue. The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the tables below: (In thousands) Three Months Three Months Three Months Revenue related to deferred revenue balance at beginning of period $ 36,151 $ 25,901 $ 22,450 Revenue related to new performance obligations satisfied during the period 45,306 55,990 59,228 Revenue recognized under "right-to-invoice" expedient 61,114 68,877 70,127 Reimbursed travel expenses, shipping and other revenue 101 130 117 Total revenue $ 142,672 $ 150,898 $ 151,922 (In thousands) Three Months Three Months Three Months Revenue related to deferred revenue balance at beginning of period $ 29,401 $ 36,770 $ 38,801 Revenue related to new performance obligations satisfied during the period 47,263 41,814 41,013 Revenue recognized under "right-to-invoice" expedient 56,811 62,105 64,531 Reimbursed travel expenses, shipping and other revenue 177 517 323 Total revenue $ 133,652 $ 141,206 $ 144,668 The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total unsatisfied performance obligations equaled $ 989 million as of September 30, 2022, of which we expect to recognize approximately 41 % over the next 12 months, and the remaining 59 % thereafter. Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment. We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount and uncertainty of our revenue and cash flows are affected by economic factors. The tables below summarize revenue by type and nature of revenue stream as well as by our reportable segment. Three Months Ended September 30, 2022 (In thousands) Veradigm Unallocated Amounts Total Provider $ 116,280 $ 6,531 $ 122,811 Payer & Life Sciences 29,111 0 29,111 Total revenue $ 145,391 $ 6,531 $ 151,922 Three Months Ended September 30, 2021 (In thousands) Veradigm Unallocated Amounts Total Provider $ 110,680 $ 7,499 $ 118,179 Payer & Life Sciences 26,489 0 26,489 Total revenue $ 137,169 $ 7,499 $ 144,668 Nine Months Ended September 30, 2022 (In thousands) Veradigm Unallocated Amounts Total Provider $ 341,229 $ 19,186 $ 360,415 Payer & Life Sciences 85,077 0 85,077 Total revenue $ 426,306 $ 19,186 $ 445,492 Nine Months Ended September 30, 2021 (In thousands) Veradigm Unallocated Amounts Total Provider $ 322,715 $ 22,538 $ 345,253 Payer & Life Sciences 74,273 0 74,273 Total revenue $ 396,988 $ 22,538 $ 419,526 Contract Assets – Estimate of Credit Losses We adopted Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) on January 1, 2020 using the cumulative-effect adjustment transition method. The guidance required the recognition of lifetime estimated credit losses expected to occur for contract assets and trade receivables. The guidance also required that we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. We segmented the contract asset population into pools based on their risk assessment. Risks related to contract assets are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment and business size. We also used each customer’s primary business unit in our pooling determination. This assessment provides information of the customer including size, segment and industry. The pools are aligned with management’s current review of financial performance. For the three and nine months ended September 30, 2022, no adjustment to the pools was necessary. We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a 24-month lookback period of credit memos and adjustments divided by the average contract asset balance for each pool during that period. We considered current economic conditions, including macroeconomic and inflationary trends and how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. The September 30, 2022 analysis resulted in a reduction to the ending estimate of credit losses. Changes in the estimate of credit losses for contract assets are presented in the table below. Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance $ 2,110 $ 2,110 Write-offs ( 345 ) 0 Ending balance $ 1,765 $ 2,110 Less: Contract assets, short-term 564 576 Total contract assets, long-term $ 1,201 $ 1,534

Accounts Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Accounts Receivable	3. Accounts Receivable Trade Accounts Receivable – Estimate of Credit Losses We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. Refer to Note 2, “Revenue from Contracts with Customers” for information regarding the adoption of ASU 2016-13. No adjustments were made to the pools or historical loss rate data for trade accounts receivable during the nine months ended September 30, 2022. Changes in the estimate of credit losses for trade accounts receivable are presented in the table below. Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance $ 13,360 $ 20,228 Current period provision 1,979 1,432 Write-offs ( 2,471 ) ( 2,291 ) Ending balance $ 12,868 $ 19,369

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Lessee Disclosure [Abstract]
Leases	4. Leases We determine whether an arrangement is a lease at inception. Assets leased under an operating lease arrangement are recorded in Right-of-use assets – operating leases and the associated lease liabilities are included in Current operating lease liabilities and Long-term operating lease liabilities within the consolidated balance sheets. Assets leased under finance lease arrangements are recorded within fixed assets and the associated lease liabilities are recorded within Accrued expenses and Other liabilities within the consolidated balance sheet. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate in conjunction with the market swap rate for the expected remaining lease term at the commencement date for new leases in determining the present value of future lease payments. Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. We have elected the group of practical expedients under Accounting Standards Update No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) to forego assessing upon adoption: (1) whether any expired contracts are or contain leases; (2) the lease classification for any existing or expired leases; and (3) any indirect costs that would have qualified for capitalization for any existing leases. We have lease agreements with lease and non-lease components, which are generally accounted for separately except for real estate leases, which we have elected to combine through a practical expedient under ASU 2016-02. Non-lease components for our leases typically consist of executory costs, and the practical expedient allows for executory costs to be recorded as lease payments. Additionally, for certain equipment leases, we apply a portfolio approach to effectively record right-of-use assets and liabilities. Our operating leases mainly include office leases, and our finance leases included office and computer equipment leases. As of December 31, 2021, we no longer have finance leases. Our finance leases in 2021 were not significant. Our operating leases have remaining lease terms up to 5 years, some of which include options to extend the leases for up to 5 years, which may include options to terminate the leases within 1 year . Operating costs associated with leased assets are as follows: (In thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease cost (1) $ 1,466 $ 1,828 $ 4,681 $ 5,652 Less: Sublease income ( 98 ) ( 61 ) ( 196 ) ( 218 ) Total operating lease costs $ 1,368 $ 1,767 $ 4,485 $ 5,434 (1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations . Supplemental cash flow information for operating leases is as follows: (In thousands) Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 5,213 $ 5,615 Right-of-use assets obtained in exchange for operating lease obligations $ 273 $ 0 The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) September 30, 2022 December 31, 2021 Right-of-use assets - operating leases $ 14,520 $ 18,324 Current operating lease liabilities $ 6,166 $ 6,133 Long-term operating lease liabilities $ 12,315 $ 16,754 Weighted average remaining lease term (in years) 4 5 Weighted average discount rate 3.3 % 3.4 % The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of September 30, 2022. September 30, 2022 (In thousands) Operating Leases Remainder of 2022 $ 1,666 2023 6,421 2024 3,706 2025 3,453 2026 2,835 Thereafter 1,581 Total lease liabilities 19,662 Less: Amount representing interest ( 1,181 ) Less: Short-term lease liabilities ( 6,166 ) Total Long-term lease liabilities $ 12,315

Business Combinations and Dives

Business Combinations and Divestitures	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Business Combinations and Divestitures	5. Business Combinations and Divestitures Acquisitions On March 25, 2022 , we acquired Babel Health, which engages in the business of designing, developing, selling and operating encounter data submission and reconciliation solutions. The base purchase price was $ 24.0 million, subject to adjustment for cash and net working capital balances, resulting in $ 24.5 million in cash paid ($ 24.0 million in net cash after accounting for the existing cash balance). The allocation of the purchase price is preliminary and subject to change. Accordingly, adjustments may be made to the values of assets and liabilities assumed as the valuation is finalized and additional information is obtained about the facts and circumstances that existed at the acquisition date. We expect to finalize the valuation and complete the purchase consideration allocation within the allowable measurement period. The management platform will provide managed health care plans with a tailored solution for the risk adjustment claims submission process. The business is included in our Veradigm reportable segment. The preliminary purchase price allocation of the fair value of the consideration transferred as of the acquisition date of March 25, 2022 is shown in the table below. The goodwill is expected to be deductible for tax purposes. (In thousands) Cash and cash equivalents $ 472 Accounts receivable, net 394 Prepaid expenses and other current assets 206 Fixed assets 48 Intangible assets 7,280 Goodwill 17,320 Other assets 217 Accounts payable and accrued expenses ( 752 ) Deferred revenue ( 675 ) Net assets acquired $ 24,510 The following table summarizes the estimated fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships 21 $ 4,640 Technology 7 2,600 Tradenames 1 40 $ 7,280 We incurred $ 0.2 million of acquisition costs during the nine months ended September 30, 2022, which are included in Selling, general and administrative expenses in our consolidated statement of operations. The results of operations of Babel Health were not material to our consolidated results of operations for the three and nine months ended September 30, 2022. Divestitures On May 2, 2022, we completed the sale of our Hospitals and Large Physician Practices business, including the Sunrise and TouchWorks solutions (the “Hospitals and Large Physician Practices Business”) to Altera Digital Health Inc. (formerly known as Harris Dawn Holdings Inc.), a Delaware corporation (“Altera”), a wholly-owned subsidiary of Constellation Software Inc., an Ontario corporation, pursuant to a purchase agreement (the “Altera Purchase Agreement”) by which Altera purchased substantially all of the assets of the Hospitals and Large Physician Practices Business. The total consideration for the Hospitals and Large Physician Practices Business was $ 670.0 million in cash paid at closing, with up to an additional $ 30.0 million of contingent consideration based on the Hospitals and Large Physician Practices Business’s revenue through calendar year 2023. Certain assets relating to the Hospitals and Large Physician Practices Business were excluded from the transaction and retained by the Company, as described in the Altera Purchase Agreement. In addition, Altera assumed certain liabilities related to the Hospitals and Large Physician Practices Business under the terms of the Altera Purchase Agreement. We realized a pre-tax gain upon the sale of $ 7.9 million, which is included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the nine months ended September 30, 2022. The divestiture was treated as a discontinued operation as of June 30, 2022. Refer to Note 15, “Discontinued Operations” for additional information regarding the historical assets, liabilities and results of operations of the Hospitals and Large Physician Practices Business. On August 23, 2021, we completed the sale of substantially all of the assets of our 2bPrecise business to a third party for a non-controlling interest in the combined entity. We realized a pre-tax gain upon the sale of $ 8.4 million, which was included in the Gain on sale of businesses, net line in our consolidated statements of operations for the year ended December 31, 2021. The historical 2bPrecise business is presented in our “Unallocated Amounts” category. On December 31, 2020, we completed the sale of substantially all of the assets of our CarePort business to a subsidiary of WellSky Corp., a Delaware corporation (“WellSky”), pursuant to a purchase agreement (the “CarePort Purchase Agreement”). The total consideration for CarePort was $ 1.35 billion, which was subject to certain adjustments for liabilities assumed by WellSky and net working capital as described in the CarePort Purchase Agreement. We realized a pre-tax gain upon the sale of $ 933.9 million, which was included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2020. For the year ended December 31, 2021, we recorded a $ 0.6 million gain that primarily related to net working capital adjustments in the Gain on sale of discontinued operations line in our consolidated statements of operations. The divestiture was treated as a discontinued operation as of December 31, 2020. Refer to Note 15, “Discontinued Operations” for additional information. On October 15, 2020, we completed the sale of substantially all of the assets of our EPSi TM business (“EPSi”) to Strata Decision Technology LLC, an Illinois limited liability company (“Strata”), and Roper Technologies, Inc., a Delaware corporation, pursuant to a purchase agreement (the “EPSi Purchase Agreement”). The total consideration for EPSi was $ 365.0 million, which was subject to certain adjustments for liabilities assumed by Strata and net working capital as described in the EPSi Purchase Agreement. We realized a pre-tax gain upon the sale of $ 222.6 million, which was included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2020. The divestiture was treated as a discontinued operation as of December 31, 2020 . Refer to Note 15, “Discontinued Operations” for additional information.

Fair Value Measurements and Lon

Fair Value Measurements and Long-term Investments	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements and Long-term Investments	6. Fair Value Measurements and Long-term Investments Fair value measurements are based upon observable and unobservable inputs. Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instrument reflects the fair value of contingent consideration related to a completed acquisition. The fair value is based on a discounted cash flow analysis reflecting the likelihood of achieving specified performance measures or events and captures the contractual nature of the contingencies, commercial risk or time value of money. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet September 30, 2022 December 31, 2021 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Foreign exchange Prepaid expenses $ 0 $ 0 $ 0 $ 0 $ 0 $ 352 $ 0 $ 352 Total assets $ 0 $ 0 $ 0 $ 0 $ 0 $ 352 $ 0 $ 352 Foreign exchange Accrued $ 0 $ 70 $ 0 $ 70 $ 0 $ 0 $ 0 $ 0 Contingent consideration Accrued 0 0 0 0 0 0 19 19 Total liabilities $ 0 $ 70 $ 0 $ 70 $ 0 $ 0 $ 19 $ 19 The changes in our Level 3 liability measured at fair value on a recurring basis at September 30, 2022 is summarized as follows: (In thousands) Contingent Consideration Balance at December 31, 2021 $ 19 Payments ( 19 ) Balance at September 30, 2022 $ 0 Long-term Investments The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at September 30, 2022 Cost September 30, 2022 December 31, 2021 Equity method investments (1) 5 $ 8,190 $ 12,053 $ 12,260 Cost with adjustments 7 47,114 49,099 49,293 Total long-term equity investments 12 $ 55,304 $ 61,152 $ 61,553 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. During the three months ended September 30, 2021, we divested one of our businesses to a new third-party in exchange for a non-controlling interest in the combined entity, which is a cost method investment. The divestiture resulted in an $ 8.4 million gain, which is included in the Gain on sale of businesses, net line in our consolidated statements of operations for the three and nine months ended September 30, 2021. During the nine months ended September 30, 2021, one of our third-party cost method investments converted its notes and we received 475 thousand shares in such third party as a result of the conversion. We also revalued our existing investment based on the note conversion share price. The note conversion and the revaluation of the existing investment resulted in a $ 9.7 million gain, which is included in the Other income, net line in our consolidated statements of operations for the nine months ended September 30, 2021. As of September 30, 2022, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments, primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations, the issuer’s subsequent or planned raises of capital and observable price changes in orderly transactions. Impairment of Long-term Investments Each quarter, management performs an assessment of each of our investments on an individual basis to determine if there have been any declines in fair value. Based on our assessment, we determined no impairment charges were necessary for the nine months ended September 30, 2022. Long-term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our Senior Secured Credit Facility (as described in Note 10, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. Refer to Note 10, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity	7. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three and nine months ended September 30, 2022 and 2021 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three and nine months ended September 30, 2022 and 2021. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Cost of revenue: Provider $ 283 $ 213 $ 821 $ 709 Payer & Life Sciences 46 52 71 158 Total cost of revenue 329 265 892 867 Selling, general and administrative expenses 3,831 2,079 17,629 6,967 Research and development 552 828 2,278 2,834 Total stock-based compensation expense $ 4,712 $ 3,172 $ 20,799 $ 10,668 Allscripts Long-Term Incentive Plan We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three and nine months ended September 30, 2022 and 2021. We granted stock-based awards as follows: Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 14 $ 15.82 1,260 $ 18.41 Performance-based restricted stock units with a service condition 0 $ 0.00 243 $ 18.56 Market-based restricted stock units with a service condition 0 $ 0.00 258 $ 21.90 14 $ 15.82 1,761 $ 18.94 During the nine months ended September 30, 2022 and the year ended December 31, 2021, 2.9 million and 2.2 million shares of common stock, respectively, were issued in connection with the release of restrictions on stock-based awards. Net Share-settlements Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax, and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the nine months ended September 30, 2022 and 2021 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the nine months ended September 30, 2022 and 2021 were 1.6 million and 900 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases On November 18, 2020, we announced that our Board of Directors approved a stock purchase program (the “2020 Program”) under which we were authorized to repurchase up to $ 300 million of our common stock through December 31, 2021. The 2020 Program replaced a previous program that was fully utilized. During the nine months ended September 30, 2021, we repurchased 5.6 million shares of our common stock under the 2020 Program for a total of $ 101.5 million, net of commissions. This was inclusive of the 1.6 million shares we received at final settlement of the accelerated share repurchase program we entered into on November 30, 2020. Please refer to Part II, Item 8 of our Form 10-K for further details on this accelerated share repurchase program. On May 26, 2021, we announced that our Board of Directors approved a stock purchase program (the “2021 Program”) under which we were authorized to repurchase up to $ 350 million of our common stock. The 2021 Program replaced the 2020 Program that was fully utilized and did not have a termination date. During the three months ended September 30, 2021, we received 2.4 million shares of our common stock for a total of $ 38.8 million at final settlement of the accelerated share repurchase program we entered into on June 14, 2021. During the nine months ended September 30, 2021, we repurchased 13.9 million shares of our common stock under the 2021 Program for a total of $ 241.7 million, net of commissions. This was inclusive of the shares we received at initial and final settlement of the accelerated share repurchase program entered into on June 14, 2021. Please refer to Part II, Item 8 of our Form 10-K for further details on this accelerated share repurchase program. On January 24, 2022, we announced that our Board of Directors approved a stock purchase program (the “2022 Program”) under which we may repurchase up to $ 250 million of our common stock, with no termination date. The 2022 Program replaced the 2021 Program that was fully utilized. During the three months ended September 30, 2022, we repurchased 1.9 million shares of our common stock under the 2022 Program for a total of $ 33.7 million, net of commissions. During the nine months ended September 30, 2022, we repurchased 9.7 million shares of our common stock under the 2022 Program for a total of $ 177.0 million, net of commissions. The approximate dollar value of shares of our common stock that may yet be purchased under the 2022 Program was $ 73.2 million as of September 30, 2022. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	8. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the numerator includes net income (loss) and any interest expense related to the 0.875% Convertible Senior Notes, net of tax, and the denominator includes both the weighted-average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of restricted stock unit awards and warrants calculated under the treasury stock method, as well as convertible notes calculated under the if-converted method. The calculations of earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2022 2021 2022 2021 Basic earnings (loss) per Common Share: Income from continuing operations, net of tax $ 10,925 $ 20,276 $ 32,658 $ 50,719 Income (loss) from discontinued operations, net of tax 3,603 ( 4,096 ) ( 59,299 ) ( 3,556 ) Net income (loss) $ 14,528 $ 16,180 $ ( 26,641 ) $ 47,163 Weighted-average common shares outstanding 110,206 123,892 113,419 133,517 Basic earnings from continuing operations per Common Share $ 0.10 $ 0.16 $ 0.29 $ 0.38 Basic earnings (loss) from discontinued operations per Common Share 0.03 ( 0.03 ) ( 0.52 ) ( 0.03 ) Net earnings (loss) per Common Share $ 0.13 $ 0.13 $ ( 0.23 ) $ 0.35 Diluted earnings (loss) per Common Share: Income from continuing operations, net of tax $ 10,925 $ 20,276 $ 32,658 $ 50,719 Effect of assumed conversions: Plus: Interest expense, net of tax, associated with 0.875% Convertible Senior Notes 506 0 1,519 0 Income from continuing operations, net of tax after the effect of assumed conversions $ 11,431 $ 20,276 $ 34,177 $ 50,719 Income (loss) from discontinued operations, net of tax $ 3,603 $ ( 4,096 ) $ ( 59,299 ) $ ( 3,556 ) Weighted-average common shares outstanding 110,206 123,892 113,419 133,517 Plus: Dilutive effect of restricted stock unit awards, convertible notes and warrants 18,665 7,460 20,861 8,564 Weighted-average common shares outstanding assuming dilution 128,871 131,352 134,280 142,081 Diluted earnings from continuing operations per Common Share $ 0.09 $ 0.15 $ 0.25 $ 0.36 Diluted (loss) earnings from discontinued operations per Common Share 0.03 ( 0.03 ) ( 0.44 ) ( 0.03 ) Net earnings (loss) per Common Share $ 0.12 $ 0.12 $ ( 0.19 ) $ 0.33 Shares of common stock underlying the following restricted stock unit awards, convertible notes and warrants are not included in the computation of diluted earnings per share as the effect of including such restricted stock unit awards, convertible notes and warrants in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Shares subject to anti-dilutive restricted stock unit awards, convertible notes and warrants excluded from calculation 1,452 1,504 180 1,502

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: September 30, 2022 December 31, 2021 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 252,083 $ ( 232,475 ) $ 19,608 $ 249,483 $ ( 227,408 ) $ 22,075 Customer contracts and relationships 402,125 ( 328,478 ) 73,647 397,445 ( 321,830 ) 75,615 Total $ 654,208 $ ( 560,953 ) $ 93,255 $ 646,928 $ ( 549,238 ) $ 97,690 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 523,927 506,607 Total $ 575,927 $ 558,607 Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2022 were as follows: (In thousands) Veradigm Unallocated Total Balance as of December 31, 2021 $ 467,630 $ 38,977 $ 506,607 Additions 17,320 0 17,320 Balance as of September 30, 2022 $ 484,950 $ 38,977 $ 523,927 There were no accumulated impairment losses associated with goodwill as of September 30, 2022 and December 31, 2021.

Debt

Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	10. Debt Debt outstanding, excluding lease obligations, consists of the following: September 30, 2022 December 31, 2021 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 207,911 $ 3,875 $ 204,036 $ 167,853 $ ( 9,057 ) $ 176,910 Senior Secured Credit Facility 0 3,710 ( 3,710 ) 175,000 1,848 173,152 Total debt $ 207,911 $ 7,585 $ 200,326 $ 342,853 $ ( 7,209 ) $ 350,062 (1) As of September 30, 2022, the principal balance is recognized in debt. As of December 31, 2021, the principal balance is $ 207,911 thousand; $ 167,853 thousand is recognized in debt and $ 40,058 thousand is recognized in additional paid-in capital. Interest expense consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Interest expense $ 816 $ 1,742 $ 3,406 $ 4,109 Amortization of discounts and debt issuance costs 430 1,875 1,863 5,600 Total interest expense $ 1,246 $ 3,617 $ 5,269 $ 9,709 Interest expense related to the 0.875 % Convertible Senior Notes included in the table above consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Coupon interest $ 454 $ 454 $ 1,364 $ 1,364 Amortization of discounts and debt issuance costs 228 1,479 684 4,412 Total interest expense related to the 0.875% Convertible Senior Notes $ 682 $ 1,933 $ 2,048 $ 5,776 Allscripts Senior Secured Credit Facility On April 29, 2022, Allscripts and Allscripts Healthcare LLC entered into a Third Amended and Restated Credit Agreement (the “Third Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent and other lenders party thereto, amending and restating the then-existing agreement (the “Second Amended Credit Agreement”). The Third Amended Credit Agreement provides for a $ 700.0 million senior secured revolving facility (the “Revolving Facility”). A total of up to $ 50.0 million of the Revolving Facility is available for the issuance of letters of credit, up to $ 25.0 million of the Revolving Facility is available for swingline loans, and up to $ 100.0 million of the Revolving Facility can be borrowed under certain foreign currencies. Proceeds from the borrowings under the Third Amended Credit Agreement were used for the refinancing of loans under the Second Amended Credit Agreement. As of September 30, 2022, $ 0.8 million in letters of credit were outstanding under the Third Amended Credit Agreement. No amounts under the Revolving Facility were outstanding under the Third Amended Credit Agreement as of September 30, 2022. We were in compliance with all covenants under the Third Amended Credit Agreement as of September 30, 2022. As of September 30, 2022, we had $ 699.2 million available borrowing capacity, net of any outstanding letters of credit, under the Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of the Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings or if we are unable to maintain compliance with applicable covenants. 0.875% Convertible Senior Notes The issuance in December 2019 of the combined $ 218.0 million aggregate principal amount of the 0.875 % Convertible Senior Notes resulted in $ 0.7 million in debt issuance costs, which were paid in January 2020. We have separately recorded liability and equity components of the 0.875% Convertible Senior Notes, including any discounts and issuance costs, by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This allocation was completed by first estimating an interest rate at the time of issuance for similar notes that do not include an embedded conversion option. The semi-annual interest rate of 1.95 % was used to compute the initial fair value of the liability component, which totaled $ 177.9 million at the time of issuance. The excess of the initial proceeds received from the 0.875% Convertible Senior Notes and the $177.9 million liability component was allocated to the equity component, which totaled $ 40.1 million at the time of issuance before deducting any paid capped call fees. The equity component of $ 40.1 million, the $ 17.2 million in paid capped call fees and an allocation of $ 1.1 million in combined discounts and issuance costs were recorded in Additional paid-in capital within the consolidated balance sheets in December 2019. These were recorded as a discount and are to be accreted into interest expense through January 1, 2027 using the interest method. In June 2020, we paid $ 7.7 million to repurchase $ 10.1 million of the aggregate principal amount of the 0.875 % Convertible Senior Notes, which resulted in a $ 0.5 million gain. In connection with the repurchase, the capped call transaction was partially terminated, and we received $ 0.3 million, which resulted in a recognition of $ 0.8 million in equity to offset the capped call fees and a $ 0.5 million loss. On January 1, 2022, we adopted ASU 2020-06 using the modified retrospective transition method. The guidance simplifies the accounting for convertible instruments by removing major separation models required under GAAP. The guidance also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions. As a result of the adoption of ASU 2020-06, the liability and equity components of the 0.875% Convertible Senior Notes are to be presented as a single liability as of January 1, 2022. Therefore, as of January 1, 2022, we decreased Additional paid-in capital by $ 38.9 million, which represented the $ 40.1 million equity component, offset by the $ 1.1 million in combined discounts and issuance costs. We increased Retained earnings by $ 12.5 million to reverse the accretion of interest expense related to the equity component that was recorded from December 2019 through December 2021. We also increased Long-term debt by $ 26.4 million, which represents the difference between the reduction to Additional paid-in capital and the increase in Retained earnings. The capped call fees remain in Additional paid-in capital within our consolidated balance sheet. The 0.875 % Convertible Senior Notes became convertible at the option of the holders during the first quarter of 2022. However, as of September 30, 2022, none of the 0.875 % Convertible Senior Notes have been converted. The remaining principal amount of the 0.875 % Convertible Senior Notes at September 30, 2022 totaled $ 207.9 million. The carrying value of the capped call fees at September 30, 2022 was $ 16.4 million. Future Debt Payments The following table summarizes future debt principal payment obligations as of September 30, 2022: (In thousands) Total Remainder 2023 2024 2025 2026 Thereafter 0.875% Convertible Senior Notes (1) $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 Total debt $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 (1) Amount represents the face value of the 0.875 % Convertible Senior Notes.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes We account for income taxes under FASB ASC 740, “ Income Taxes” (“ASC 740”). We calculate the quarterly tax provision consistent with the guidance provided by ASC 740, whereby we forecast the estimated annual effective tax rate and then apply that rate to the year-to-date pre-tax book (loss) income. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective rate, including factors such as the valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, or changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. There is no tax benefit recognized on certain of the net operating losses incurred due to insufficient evidence supporting the Company’s ability to use these losses in the future. The effective tax rates were as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except effective tax rate) 2022 2021 2022 2021 Income from continuing operations before income taxes $ 24,793 $ 27,466 $ 23,526 $ 63,183 Income tax (provision) benefit $ ( 13,868 ) $ ( 7,190 ) $ 9,132 $ ( 12,464 ) Effective tax rate 55.9 % 26.2 % 38.8 % 19.7 % NM - We define “NM” as not meaningful for percentages greater than 200%. Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate primarily due to permanent differences, income attributable to foreign jurisdictions taxed at different rates, state taxes, tax credits and certain discrete items including a windfall benefit of $ 12.6 million for the nine months ended September 30, 2022 and a windfall benefit of $ 4.6 million for the nine months ended September 30, 2021. Our effective tax rates for the three and nine months ended September 30, 2022, compared with the prior year comparable periods, differ primarily due to the release of valuation allowance of $ 11.2 million in both the three and nine months ended September 30, 2022. In addition, the permanent items, credits and the impact of foreign earnings had more impact on the pre-tax income of $ 24.8 million and $ 23.5 million in the three and nine months ended September 30, 2022, compared to the impact of these items on a pre-tax income of $ 27.5 million and $ 63.2 million for the three and nine months ended September 30, 2021. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). During the nine months ended September 30, 2022, we released valuation allowances of $ 11.2 million related to U.S. deferred tax assets. Our unrecognized income tax benefits were $ 31.7 million and $ 30.3 million as of September 30, 2022 and December 31, 2021, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted considering changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	12. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: September 30, 2022 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 70 Total derivatives $ 0 $ 70 December 31, 2021 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 352 Accrued expenses $ 0 Total derivatives $ 352 $ 0 Foreign Exchange Contracts We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a percentage of forecasted monthly INR expenses over time. As of September 30, 2022, there were three forward contracts outstanding that when entered into were staggered to mature monthly starting in October 2022 and ending in December 2022 . In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2022. As of September 30, 2022, the notional amount for each of the outstanding forward contracts was 50 million INR, or the equivalent of $ 0.6 million, based on the exchange rate between the United States dollar and the INR in effect as of September 30, 2022. These amounts also approximate the forecasted future INR expenses we target to hedge in any one month in the future. As of September 30, 2022, we estimate that $ 0.1 million of net unrealized derivative losses included in accumulated other comprehensive income (loss) (“AOCI”) will be reclassified into income within the next 12 months . The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive income (loss): Amount of Gain (Loss) Recognized Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Nine Months Location of Gain (Loss) Reclassified Three Months Nine Months Foreign exchange contracts $ ( 76 ) $ ( 379 ) Cost of Revenue $ ( 21 ) $ 15 Selling, general and ( 14 ) 9 Research and development ( 25 ) 17 Amount of Gain (Loss) Recognized Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Nine Months Location of Gain (Loss) Reclassified Three Months Nine Months Foreign exchange contracts $ 0 $ 121 Cost of Revenue $ 0 $ 611 Selling, general and 0 351 Research and development 0 668

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Accumulated Other Comprehensive Loss	13. Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2021 (1) $ ( 3,026 ) $ 261 $ ( 2,765 ) Other comprehensive (loss) income before ( 808 ) ( 282 ) ( 1,090 ) Net (gains) losses reclassified from accumulated 0 ( 31 ) ( 31 ) Net other comprehensive income (loss) ( 808 ) ( 313 ) ( 1,121 ) Balance as of September 30, 2022 (2) $ ( 3,834 ) $ ( 52 ) $ ( 3,886 ) (1) Net of taxes of $ 91 thousand for unrealized net gains on foreign exchange contract derivatives. (2) Net of taxes of $ 18 thousand for unrealized net losses on foreign exchange contract derivatives. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2020 (1) $ ( 2,957 ) $ 1,119 $ ( 1,838 ) Other comprehensive (loss) income before ( 285 ) 90 ( 195 ) Net (gains) losses reclassified from accumulated 0 ( 1,209 ) ( 1,209 ) Net other comprehensive income (loss) ( 285 ) ( 1,119 ) ( 1,404 ) Balance as of September 30, 2021 $ ( 3,242 ) $ 0 $ ( 3,242 ) (1) Net of taxes of $ 390 thousand for unrealized net gains on foreign exchange contract derivatives. Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended September 30, 2022 2021 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 59 $ 0 $ 59 $ ( 805 ) $ 0 $ ( 805 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period ( 76 ) 20 ( 56 ) 0 0 0 Net losses (gains) reclassified into income 60 ( 15 ) 45 0 0 0 Net change in unrealized (losses) gains on foreign exchange contracts ( 16 ) 5 ( 11 ) 0 0 0 Other comprehensive income (loss) $ 43 $ 5 $ 48 $ ( 805 ) $ 0 $ ( 805 ) Nine Months Ended September 30, 2022 2021 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ ( 808 ) $ 0 $ ( 808 ) $ ( 285 ) $ 0 $ ( 285 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period ( 379 ) 97 ( 282 ) 121 ( 31 ) 90 Net (gains) losses reclassified into income ( 41 ) 10 ( 31 ) ( 1,630 ) 421 ( 1,209 ) Net change in unrealized (losses) gains on foreign exchange contracts ( 420 ) 107 ( 313 ) ( 1,509 ) 390 ( 1,119 ) Other comprehensive (loss) income $ ( 1,228 ) $ 107 $ ( 1,121 ) $ ( 1,794 ) $ 390 $ ( 1,404 )

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	14. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves, as appropriate, in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results. The Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation (“McKesson”) on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York related to the Horizon Clinicals software. In August 2018, McKesson received an additional CID (together with the May 2017 CID, the “McKesson CIDs”), related to the Paragon software. The McKesson CIDs request documents and information related to the certification McKesson obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. McKesson has agreed, with respect to the McKesson CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition. In October 2021, Allscripts received a CID seeking information about its acquisition of the EIS Business from McKesson and the Horizon Clinicals software. McKesson has agreed to assume defense of this CID. In May 2022, Allscripts completed the sale of substantially all of the assets of its Hospitals and Large Physician Practices Business to Altera. This divestiture included the sale of the Paragon software; however, the divestiture did not include the Horizon Clinicals software or liabilities arising from the McKesson CIDs. Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. Between April 2018 and June 2019, Practice Fusion received from the U.S. Department of Justice (the “DOJ”) seven additional requests for documents and information through four additional CIDs and three Health Insurance Portability and Accountability Act (“HIPAA”) subpoenas. The document and information requests received by Practice Fusion related to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program and Practice Fusion’s compliance with the Anti-Kickback Statute (“AKS”) and HIPAA as it relates to certain business practices engaged in by Practice Fusion. In March 2019, Practice Fusion received a grand jury subpoena in connection with a criminal investigation related to Practice Fusion’s compliance with the AKS. On August 6, 2019, Practice Fusion reached an agreement in principle with the DOJ to resolve all of the DOJ’s outstanding civil and criminal investigations, including the investigation by the U.S. Attorney’s Office for the District of Vermont, and we announced that on January 27, 2020, Practice Fusion entered into a deferred prosecution agreement (the “Deferred Prosecution Agreement”) and various civil settlement agreements, including with the Medicaid programs for each U.S. state, the District of Columbia and Puerto Rico (collectively, the “Settlement Agreements”) resolving the investigations conducted by the DOJ and the U.S. Attorney’s Office. The Settlement Agreements required Practice Fusion to, among other things, pay a criminal fine of $ 25.3 million, a forfeiture payment of $ 959,700 and a civil settlement of $ 118.6 million, which includes $ 5.2 million designated for the state Medicaid program expenditures, all of which, as of December 31, 2020, were paid in full. The Deferred Prosecution Agreement required Practice Fusion to retain an “Oversight Organization” to oversee the Practice Fusion’s implementation of certain compliance measures and ongoing compliance efforts. On August 17, 2021, Practice Fusion’s initial Oversight Organization resigned, and on August 25, 2021, Practice Fusion received a notice from the U.S. Attorney’s Office for the District of Vermont stating Practice Fusion was in breach of the Deferred Prosecution Agreement due to such resignation. On September 17, 2021, Practice Fusion engaged a new Oversight Organization. On March 18, 2022, Practice Fusion reached a settlement with the U.S. Attorney’s Office concerning this claim, pursuant to which Practice Fusion agreed to pay $ 200,000 to the United States and extend the Deferred Prosecution Agreement by 11 weeks; Practice Fusion did not admit liability for any breach of the Deferred Prosecution Agreement. The settlement of $ 200,000 was paid by Practice Fusion on April 5, 2022.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	15. Discontinued Operations Hospitals and Large Physician Practices Discontinued Operation On May 2, 2022, we sold substantially all of the assets of the Hospitals and Large Physician Practices Business. The Hospitals and Large Physician Practices Business sale represented a strategic shift that had a major effect on our operations and financial results. As of September 30, 2022, we reported the Hospitals and Large Physician Practices Business as discontinued operations. Prior to the sale, the Hospitals and Large Physician Practices Business was part of the former Hospitals and Large Physician Practices reportable segment. The following table summarizes the major classes of assets and liabilities of the Hospitals and Large Physician Practices Business as reported on the consolidated balance sheets as of September 30, 2022 and December 31, 2021: (In thousands) September 30, 2022 December 31, 2021 Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations: Cash and cash equivalents $ 8,000 $ 55,834 Restricted cash 0 861 Accounts receivable, net of allowance of $ 16,584 as of December 31, 2021 0 155,447 Contract assets, net of allowance of $ 492 as of December 31, 2021 0 61,382 Prepaid expenses and other current assets 0 58,431 Total current assets attributable to discontinued operations 8,000 331,955 Fixed assets, net 0 38,083 Software development costs, net 0 97,416 Intangible assets, net 0 86,240 Goodwill 0 467,871 Deferred taxes, net 0 6,607 Contract assets - long-term, net of allowance of $ 739 as of December 31, 2021 0 28,623 Right-of-use assets - operating leases 0 50,585 Other assets 0 17,731 Total long-term assets attributable to discontinued operations $ 0 $ 793,156 Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations: Accounts payable $ 17,687 $ 11,555 Accrued expenses 0 38,007 Income tax payable 925 0 Accrued compensation and benefits 0 61,167 Deferred revenue 0 205,152 Current operating lease liabilities 0 13,466 Total current liabilities attributable to discontinued operations 18,612 329,347 Deferred revenue long-term 0 2,568 Long-term operating lease liabilities 0 48,068 Other liabilities 0 270 Total long-term liabilities attributable to discontinued operations $ 0 $ 50,906 The following table summarizes the major income and expense line items of the Hospitals and Large Physician Practices Business as reported in the consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021. The activity during the three months ended September 30, 2022 relates to certain adjustments made in connection with the sale of the Hospitals and Large Physician Practices Business, primarily relating to net working capital adjustments that impacted the gain on the sale of the discontinued operations. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Major income and expense line items related to Hospitals and Large Physician Practices: Revenue: Provider $ ( 8 ) $ 224,605 $ 284,791 $ 691,813 Total revenue ( 8 ) 224,605 284,791 691,813 Cost of revenue: Provider 32 145,487 189,530 442,234 Total cost of revenue 32 145,487 189,530 442,234 Gross (loss) profit ( 40 ) 79,118 95,261 249,579 Selling, general and administrative expenses 369 51,384 68,900 151,895 Research and development 25 24,498 32,011 83,288 Asset impairment charges 0 6,160 0 11,232 Amortization of intangible assets 0 3,455 3,538 10,376 Loss from discontinued operations for Hospitals and Large Physician Practices ( 434 ) ( 6,379 ) ( 9,188 ) ( 7,212 ) Other income, net 0 206 12 674 Gain on sale of discontinued operations 5,174 0 7,939 0 Equity in net (loss) income of unconsolidated investments 0 0 ( 76 ) 0 Income (loss) from discontinued operations for Hospitals and Large Physician Practices before income taxes 4,740 ( 6,173 ) ( 1,313 ) ( 6,538 ) Income tax (provision) benefit ( 1,137 ) 2,091 ( 57,986 ) 2,511 Income (loss) from discontinued operations, net of tax for Hospitals and Large Physician Practices $ 3,603 $ ( 4,082 ) $ ( 59,299 ) $ ( 4,027 ) EPSi and CarePort Discontinued Operations During 2020, we implemented a strategic initiative to sell two of our businesses, EPSi and CarePort. Since both businesses were part of the same strategic initiative and were sold within the same period, the combined sale of EPSi and CarePort represented a strategic shift that had a major effect on our operations and financial results. As of December 31, 2020, these businesses were reported together as discontinued operations. On October 15, 2020, we completed the sale of our EPSi business. Prior to the sale, EPSi was part of the “Unallocated Amounts” category as it did not meet the requirements to be a reportable segment nor the criteria to be aggregated into our two reportable segments at this time. On its own, the divestiture of the EPSi business did not represent a strategic shift that had a major effect on our operations and financial results. However, the combined sale of EPSi and CarePort represented a strategic shift that had a major effect on our operations and financial results. Therefore, EPSi was treated as a discontinued operation. On December 31, 2020, we completed the sale of our CarePort business. Prior to the sale, CarePort was part of the former Data, Analytics and Care Coordination reportable segment. On its own, the divestiture of the CarePort business represented a strategic shift that had a major effect on our operations and financial results. The following table summarizes the major income and expense line items of EPSi and CarePort as reported in the consolidated statements of operations for the three and nine months ended September 30, 2021. The activity during the three and nine months ended September 30, 2021 relates to certain adjustments made in connection with the sale of EPSi and CarePort, primarily relating to net working capital adjustments that impacted the gain on the sale of the discontinued operations. Three Months Ended Nine Months Ended (In thousands) September 30, 2021 September 30, 2021 Major income and expense line items related to EPSi and CarePort: Revenue: Provider $ 6 $ 6 Total revenue 6 6 Cost of revenue: Provider 19 ( 29 ) Total cost of revenue 19 ( 29 ) Gross (loss) profit ( 13 ) 35 Selling, general and administrative expenses 2 76 Research and development 0 ( 32 ) Loss from discontinued operations for EPSi and CarePort ( 15 ) ( 9 ) Other income, net 1 2 Gain on sale of discontinued operations 0 647 (Loss) income from discontinued operations for EPSi and CarePort before income taxes ( 14 ) 640 Income tax provision 0 ( 169 ) (Loss) income from discontinued operations, net of tax for EPSi and CarePort $ ( 14 ) $ 471

Business Segments

Business Segments	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Business Segments	16. Business Segments Our two primary revenue streams are (i) provider revenue and (ii) payer and life sciences revenue. We primarily derive our provider revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services, such as outsourcing, private cloud hosting and revenue cycle management. Payer and life sciences revenue primarily consists of sales of our integrated data systems solutions and related services to key healthcare stakeholders, including health plans and pharmaceutical companies, to help them improve the quality, efficiency and value of healthcare delivery. As of January 1, 2022, we had three operating segments: (i) Hospitals and Large Physician Practices, (ii) Veradigm and (iii) Certain Products (as defined below). The Hospitals and Large Physician Practices and Veradigm operating segments were equivalent to the two reportable segments described below. The Hospitals and Large Physician Practices segment derived its revenue from the sale of integrated clinical and financial management solutions, which primarily included EHR-related software, related installation, support and maintenance, outsourcing and private cloud hosting. The Veradigm segment derived its revenue from payer and life sciences solutions, which are mainly targeted at payers, life sciences companies and other key healthcare stakeholders. Additionally, revenue was derived from software applications for patient engagement and the sale of EHR software to single-specialty and small and mid-sized physician practices, including related clinical, financial, administrative and operational solutions. These solutions enabled clients to transition, analyze and coordinate care and improve the quality, efficiency and value of healthcare delivery across the entire care community. The “Unallocated Amounts” category consisted of the 2bPrecise business, certain products that were shifted from the previous Core Clinical and Financial Solutions reportable segment due to the organizational changes (“Certain Products”), transfer pricing revenues and certain corporate-related expenses. The amounts included in the “Unallocated Amounts” category for 2bPrecise and Certain Products did not meet the requirements to be reportable segments nor the criteria to be aggregated into the two reportable segments. On March 2, 2022, we entered into a purchase agreement to sell substantially all of the assets of our Hospitals and Large Physician Practices Business. As of March 31, 2022, the assets and liabilities related to the purchase agreement were classified as held for sale on our consolidated balance sheet. We also classified the related assets and liabilities in discontinued operations, as the Hospitals and Large Physician Practices Business disposition represented a strategic shift that had a major effect on our operations and financial results. As a result of the transaction, we realigned our reporting structure. As of March 31, 2022, we had two operating segments: (i) Veradigm and (ii) Certain Products. The Veradigm operating segment was the equivalent to our one reportable segment. On May 2, 2022, we completed the sale of the Hospitals and Large Physician Practices Business. As of September 30, 2022, our two operating segments and one reportable segment remain unchanged from the end of the first quarter of 2022. The prior period segment disclosures below have been revised to conform to the current period presentation. Our chief operating decision maker uses segment revenues, gross profit and income (loss) from operations as measures of performance and to make decisions about the allocation of resources. We do not track our assets by segment. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Revenue: Veradigm $ 145,391 $ 137,169 $ 426,306 $ 396,988 Unallocated Amounts 6,531 7,499 19,186 22,538 Total revenue $ 151,922 $ 144,668 $ 445,492 $ 419,526 Gross profit: Veradigm $ 78,801 $ 65,696 $ 223,405 $ 187,960 Unallocated Amounts 4,635 3,944 12,994 13,016 Total gross profit $ 83,436 $ 69,640 $ 236,399 $ 200,976 Income (loss) from operations: Veradigm $ 27,707 $ 17,099 $ 69,796 $ 46,607 Unallocated Amounts ( 2,706 ) 1,385 ( 43,579 ) ( 3,576 ) Total income (loss) from operations $ 25,001 $ 18,484 $ 26,217 $ 43,031

Supplemental Disclosures

Supplemental Disclosures	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Disclosures	17. Supplemental Disclosures Supplemental Consolidated Statements of Cash Flows Information The majority of the restricted cash balance as of September 30, 2022 and 2021 represents lease deposits. September 30, (In thousands) 2022 2021 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 492,597 $ 142,333 Restricted cash 1,307 1,307 Total cash, cash equivalents and restricted cash $ 493,904 $ 143,640 Nine Months Ended September 30, (In thousands) 2022 2021 Supplemental non-cash information: Sale of 2bPrecise business in exchange for a non-controlling interest in the combined entity $ 0 $ 11,768 Issuance of treasury stock to commercial partner $ 0 $ 534

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year ending December 31, 2022. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the current economic conditions, including macroeconomic and inflationary trends, and the economic impact of the COVID-19 pandemic, on our critical and significant accounting estimates. Actual results could differ materially from these estimates.
Recently Adopted Accounting Pronouncements	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The amendments in ASU 2020-06 simplify the accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also requires the application of the if-converted method for calculating diluted earnings per share, whereas the treasury stock method is no longer permitted for convertible instruments. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition, which resulted in an increase in long-term debt of $ 26.4 million, a decrease in additional paid-in capital of $ 38.9 million and an increase to retained earnings of $ 12.5 million, as of January 1, 2022. Refer to Note 10, “Debt” for additional information.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In October 2021, the FASB issued Accounting Standards Update No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”), which requires contract assets and contract liabilities (deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification (“ASC”) 606, “ Revenue from Contracts with Customers” , as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, “ Business Combinations” . The new standard should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The standard is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the effects of the adoption of ASU 2021-08 on our consolidated financial statements. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.
Revenue Recognition	Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients	The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the tables below: (In thousands) Three Months Three Months Three Months Revenue related to deferred revenue balance at beginning of period $ 36,151 $ 25,901 $ 22,450 Revenue related to new performance obligations satisfied during the period 45,306 55,990 59,228 Revenue recognized under "right-to-invoice" expedient 61,114 68,877 70,127 Reimbursed travel expenses, shipping and other revenue 101 130 117 Total revenue $ 142,672 $ 150,898 $ 151,922 (In thousands) Three Months Three Months Three Months Revenue related to deferred revenue balance at beginning of period $ 29,401 $ 36,770 $ 38,801 Revenue related to new performance obligations satisfied during the period 47,263 41,814 41,013 Revenue recognized under "right-to-invoice" expedient 56,811 62,105 64,531 Reimbursed travel expenses, shipping and other revenue 177 517 323 Total revenue $ 133,652 $ 141,206 $ 144,668
Summary of Changes in Estimate of Credit Losses for Contract Assets	Changes in the estimate of credit losses for contract assets are presented in the table below. Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance $ 2,110 $ 2,110 Write-offs ( 345 ) 0 Ending balance $ 1,765 $ 2,110 Less: Contract assets, short-term 564 576 Total contract assets, long-term $ 1,201 $ 1,534
Revenue by Segment [Member]
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	The tables below summarize revenue by type and nature of revenue stream as well as by our reportable segment. Three Months Ended September 30, 2022 (In thousands) Veradigm Unallocated Amounts Total Provider $ 116,280 $ 6,531 $ 122,811 Payer & Life Sciences 29,111 0 29,111 Total revenue $ 145,391 $ 6,531 $ 151,922 Three Months Ended September 30, 2021 (In thousands) Veradigm Unallocated Amounts Total Provider $ 110,680 $ 7,499 $ 118,179 Payer & Life Sciences 26,489 0 26,489 Total revenue $ 137,169 $ 7,499 $ 144,668 Nine Months Ended September 30, 2022 (In thousands) Veradigm Unallocated Amounts Total Provider $ 341,229 $ 19,186 $ 360,415 Payer & Life Sciences 85,077 0 85,077 Total revenue $ 426,306 $ 19,186 $ 445,492 Nine Months Ended September 30, 2021 (In thousands) Veradigm Unallocated Amounts Total Provider $ 322,715 $ 22,538 $ 345,253 Payer & Life Sciences 74,273 0 74,273 Total revenue $ 396,988 $ 22,538 $ 419,526

Accounts Receivable (Tables)

Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2022
Trade Accounts Receivable [Member]
Accounts Notes And Loans Receivable [Line Items]
Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable	Changes in the estimate of credit losses for trade accounts receivable are presented in the table below. Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance $ 13,360 $ 20,228 Current period provision 1,979 1,432 Write-offs ( 2,471 ) ( 2,291 ) Ending balance $ 12,868 $ 19,369

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Lessee Disclosure [Abstract]
Summary of Operating Costs Associated with Leased Assets	Operating costs associated with leased assets are as follows: (In thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease cost (1) $ 1,466 $ 1,828 $ 4,681 $ 5,652 Less: Sublease income ( 98 ) ( 61 ) ( 196 ) ( 218 ) Total operating lease costs $ 1,368 $ 1,767 $ 4,485 $ 5,434 (1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations .
Supplemental Cash Flow Information for Operating Leases	Supplemental cash flow information for operating leases is as follows: (In thousands) Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 5,213 $ 5,615 Right-of-use assets obtained in exchange for operating lease obligations $ 273 $ 0
Summary of Balance Sheet Location and Balances for Operating Leases	The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) September 30, 2022 December 31, 2021 Right-of-use assets - operating leases $ 14,520 $ 18,324 Current operating lease liabilities $ 6,166 $ 6,133 Long-term operating lease liabilities $ 12,315 $ 16,754 Weighted average remaining lease term (in years) 4 5 Weighted average discount rate 3.3 % 3.4 %
Summary of Future Maturities of Lease and Non-Lease Components	The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of September 30, 2022. September 30, 2022 (In thousands) Operating Leases Remainder of 2022 $ 1,666 2023 6,421 2024 3,706 2025 3,453 2026 2,835 Thereafter 1,581 Total lease liabilities 19,662 Less: Amount representing interest ( 1,181 ) Less: Short-term lease liabilities ( 6,166 ) Total Long-term lease liabilities $ 12,315

Business Combinations and Div_2

Business Combinations and Divestitures (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The preliminary purchase price allocation of the fair value of the consideration transferred as of the acquisition date of March 25, 2022 is shown in the table below. The goodwill is expected to be deductible for tax purposes. (In thousands) Cash and cash equivalents $ 472 Accounts receivable, net 394 Prepaid expenses and other current assets 206 Fixed assets 48 Intangible assets 7,280 Goodwill 17,320 Other assets 217 Accounts payable and accrued expenses ( 752 ) Deferred revenue ( 675 ) Net assets acquired $ 24,510
Schedule Of estimated fair values of the identifiable intangible assets and their estimated useful lives	The following table summarizes the estimated fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships 21 $ 4,640 Technology 7 2,600 Tradenames 1 40 $ 7,280

Fair Value Measurements and L_2

Fair Value Measurements and Long-term Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet September 30, 2022 December 31, 2021 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Foreign exchange Prepaid expenses $ 0 $ 0 $ 0 $ 0 $ 0 $ 352 $ 0 $ 352 Total assets $ 0 $ 0 $ 0 $ 0 $ 0 $ 352 $ 0 $ 352 Foreign exchange Accrued $ 0 $ 70 $ 0 $ 70 $ 0 $ 0 $ 0 $ 0 Contingent consideration Accrued 0 0 0 0 0 0 19 19 Total liabilities $ 0 $ 70 $ 0 $ 70 $ 0 $ 0 $ 19 $ 19
Summary of Changes in Assets and Liability Measured at Fair Value on Recurring Basis	The changes in our Level 3 liability measured at fair value on a recurring basis at September 30, 2022 is summarized as follows: (In thousands) Contingent Consideration Balance at December 31, 2021 $ 19 Payments ( 19 ) Balance at September 30, 2022 $ 0
Long-Term Equity and Cost Method Investments [Member]
Summary of Long-term Equity Investments Included in Other Assets	The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at September 30, 2022 Cost September 30, 2022 December 31, 2021 Equity method investments (1) 5 $ 8,190 $ 12,053 $ 12,260 Cost with adjustments 7 47,114 49,099 49,293 Total long-term equity investments 12 $ 55,304 $ 61,152 $ 61,553 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Share-Based Compensation Expense	Stock-based compensation expense recognized during the three and nine months ended September 30, 2022 and 2021 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three and nine months ended September 30, 2022 and 2021. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Cost of revenue: Provider $ 283 $ 213 $ 821 $ 709 Payer & Life Sciences 46 52 71 158 Total cost of revenue 329 265 892 867 Selling, general and administrative expenses 3,831 2,079 17,629 6,967 Research and development 552 828 2,278 2,834 Total stock-based compensation expense $ 4,712 $ 3,172 $ 20,799 $ 10,668
Share-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 14 $ 15.82 1,260 $ 18.41 Performance-based restricted stock units with a service condition 0 $ 0.00 243 $ 18.56 Market-based restricted stock units with a service condition 0 $ 0.00 258 $ 21.90 14 $ 15.82 1,761 $ 18.94

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2022 2021 2022 2021 Basic earnings (loss) per Common Share: Income from continuing operations, net of tax $ 10,925 $ 20,276 $ 32,658 $ 50,719 Income (loss) from discontinued operations, net of tax 3,603 ( 4,096 ) ( 59,299 ) ( 3,556 ) Net income (loss) $ 14,528 $ 16,180 $ ( 26,641 ) $ 47,163 Weighted-average common shares outstanding 110,206 123,892 113,419 133,517 Basic earnings from continuing operations per Common Share $ 0.10 $ 0.16 $ 0.29 $ 0.38 Basic earnings (loss) from discontinued operations per Common Share 0.03 ( 0.03 ) ( 0.52 ) ( 0.03 ) Net earnings (loss) per Common Share $ 0.13 $ 0.13 $ ( 0.23 ) $ 0.35 Diluted earnings (loss) per Common Share: Income from continuing operations, net of tax $ 10,925 $ 20,276 $ 32,658 $ 50,719 Effect of assumed conversions: Plus: Interest expense, net of tax, associated with 0.875% Convertible Senior Notes 506 0 1,519 0 Income from continuing operations, net of tax after the effect of assumed conversions $ 11,431 $ 20,276 $ 34,177 $ 50,719 Income (loss) from discontinued operations, net of tax $ 3,603 $ ( 4,096 ) $ ( 59,299 ) $ ( 3,556 ) Weighted-average common shares outstanding 110,206 123,892 113,419 133,517 Plus: Dilutive effect of restricted stock unit awards, convertible notes and warrants 18,665 7,460 20,861 8,564 Weighted-average common shares outstanding assuming dilution 128,871 131,352 134,280 142,081 Diluted earnings from continuing operations per Common Share $ 0.09 $ 0.15 $ 0.25 $ 0.36 Diluted (loss) earnings from discontinued operations per Common Share 0.03 ( 0.03 ) ( 0.44 ) ( 0.03 ) Net earnings (loss) per Common Share $ 0.12 $ 0.12 $ ( 0.19 ) $ 0.33
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	following restricted stock unit awards, convertible notes and warrants are not included in the computation of diluted earnings per share as the effect of including such restricted stock unit awards, convertible notes and warrants in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Shares subject to anti-dilutive restricted stock unit awards, convertible notes and warrants excluded from calculation 1,452 1,504 180 1,502

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: September 30, 2022 December 31, 2021 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 252,083 $ ( 232,475 ) $ 19,608 $ 249,483 $ ( 227,408 ) $ 22,075 Customer contracts and relationships 402,125 ( 328,478 ) 73,647 397,445 ( 321,830 ) 75,615 Total $ 654,208 $ ( 560,953 ) $ 93,255 $ 646,928 $ ( 549,238 ) $ 97,690 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 523,927 506,607 Total $ 575,927 $ 558,607
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2022 were as follows: (In thousands) Veradigm Unallocated Total Balance as of December 31, 2021 $ 467,630 $ 38,977 $ 506,607 Additions 17,320 0 17,320 Balance as of September 30, 2022 $ 484,950 $ 38,977 $ 523,927

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Instrument [Line Items]
Debt Outstanding Excluding Lease Obligations	Debt outstanding, excluding lease obligations, consists of the following: September 30, 2022 December 31, 2021 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 207,911 $ 3,875 $ 204,036 $ 167,853 $ ( 9,057 ) $ 176,910 Senior Secured Credit Facility 0 3,710 ( 3,710 ) 175,000 1,848 173,152 Total debt $ 207,911 $ 7,585 $ 200,326 $ 342,853 $ ( 7,209 ) $ 350,062 (1) As of September 30, 2022, the principal balance is recognized in debt. As of December 31, 2021, the principal balance is $ 207,911 thousand; $ 167,853 thousand is recognized in debt and $ 40,058 thousand is recognized in additional paid-in capital.
Interest Expense	Interest expense consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Interest expense $ 816 $ 1,742 $ 3,406 $ 4,109 Amortization of discounts and debt issuance costs 430 1,875 1,863 5,600 Total interest expense $ 1,246 $ 3,617 $ 5,269 $ 9,709
Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes	Interest expense related to the 0.875 % Convertible Senior Notes included in the table above consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Coupon interest $ 454 $ 454 $ 1,364 $ 1,364 Amortization of discounts and debt issuance costs 228 1,479 684 4,412 Total interest expense related to the 0.875% Convertible Senior Notes $ 682 $ 1,933 $ 2,048 $ 5,776
Summary of Future Debt Payment Obligations	The following table summarizes future debt principal payment obligations as of September 30, 2022: (In thousands) Total Remainder 2023 2024 2025 2026 Thereafter 0.875% Convertible Senior Notes (1) $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 Total debt $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 (1) Amount represents the face value of the 0.875 % Convertible Senior Notes.

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective Tax Rates	The effective tax rates were as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except effective tax rate) 2022 2021 2022 2021 Income from continuing operations before income taxes $ 24,793 $ 27,466 $ 23,526 $ 63,183 Income tax (provision) benefit $ ( 13,868 ) $ ( 7,190 ) $ 9,132 $ ( 12,464 ) Effective tax rate 55.9 % 26.2 % 38.8 % 19.7 %

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: September 30, 2022 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 70 Total derivatives $ 0 $ 70 December 31, 2021 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 352 Accrued expenses $ 0 Total derivatives $ 352 $ 0
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive income (loss): Amount of Gain (Loss) Recognized Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Nine Months Location of Gain (Loss) Reclassified Three Months Nine Months Foreign exchange contracts $ ( 76 ) $ ( 379 ) Cost of Revenue $ ( 21 ) $ 15 Selling, general and ( 14 ) 9 Research and development ( 25 ) 17 Amount of Gain (Loss) Recognized Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Nine Months Location of Gain (Loss) Reclassified Three Months Nine Months Foreign exchange contracts $ 0 $ 121 Cost of Revenue $ 0 $ 611 Selling, general and 0 351 Research and development 0 668

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2021 (1) $ ( 3,026 ) $ 261 $ ( 2,765 ) Other comprehensive (loss) income before ( 808 ) ( 282 ) ( 1,090 ) Net (gains) losses reclassified from accumulated 0 ( 31 ) ( 31 ) Net other comprehensive income (loss) ( 808 ) ( 313 ) ( 1,121 ) Balance as of September 30, 2022 (2) $ ( 3,834 ) $ ( 52 ) $ ( 3,886 ) (1) Net of taxes of $ 91 thousand for unrealized net gains on foreign exchange contract derivatives. (2) Net of taxes of $ 18 thousand for unrealized net losses on foreign exchange contract derivatives. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2020 (1) $ ( 2,957 ) $ 1,119 $ ( 1,838 ) Other comprehensive (loss) income before ( 285 ) 90 ( 195 ) Net (gains) losses reclassified from accumulated 0 ( 1,209 ) ( 1,209 ) Net other comprehensive income (loss) ( 285 ) ( 1,119 ) ( 1,404 ) Balance as of September 30, 2021 $ ( 3,242 ) $ 0 $ ( 3,242 ) (1) Net of taxes of $ 390 thousand for unrealized net gains on foreign exchange contract derivatives.
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended September 30, 2022 2021 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 59 $ 0 $ 59 $ ( 805 ) $ 0 $ ( 805 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period ( 76 ) 20 ( 56 ) 0 0 0 Net losses (gains) reclassified into income 60 ( 15 ) 45 0 0 0 Net change in unrealized (losses) gains on foreign exchange contracts ( 16 ) 5 ( 11 ) 0 0 0 Other comprehensive income (loss) $ 43 $ 5 $ 48 $ ( 805 ) $ 0 $ ( 805 ) Nine Months Ended September 30, 2022 2021 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ ( 808 ) $ 0 $ ( 808 ) $ ( 285 ) $ 0 $ ( 285 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period ( 379 ) 97 ( 282 ) 121 ( 31 ) 90 Net (gains) losses reclassified into income ( 41 ) 10 ( 31 ) ( 1,630 ) 421 ( 1,209 ) Net change in unrealized (losses) gains on foreign exchange contracts ( 420 ) 107 ( 313 ) ( 1,509 ) 390 ( 1,119 ) Other comprehensive (loss) income $ ( 1,228 ) $ 107 $ ( 1,121 ) $ ( 1,794 ) $ 390 $ ( 1,404 )

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Discontinued Operations in Financial Statements	The following table summarizes the major classes of assets and liabilities of the Hospitals and Large Physician Practices Business as reported on the consolidated balance sheets as of September 30, 2022 and December 31, 2021: (In thousands) September 30, 2022 December 31, 2021 Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations: Cash and cash equivalents $ 8,000 $ 55,834 Restricted cash 0 861 Accounts receivable, net of allowance of $ 16,584 as of December 31, 2021 0 155,447 Contract assets, net of allowance of $ 492 as of December 31, 2021 0 61,382 Prepaid expenses and other current assets 0 58,431 Total current assets attributable to discontinued operations 8,000 331,955 Fixed assets, net 0 38,083 Software development costs, net 0 97,416 Intangible assets, net 0 86,240 Goodwill 0 467,871 Deferred taxes, net 0 6,607 Contract assets - long-term, net of allowance of $ 739 as of December 31, 2021 0 28,623 Right-of-use assets - operating leases 0 50,585 Other assets 0 17,731 Total long-term assets attributable to discontinued operations $ 0 $ 793,156 Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations: Accounts payable $ 17,687 $ 11,555 Accrued expenses 0 38,007 Income tax payable 925 0 Accrued compensation and benefits 0 61,167 Deferred revenue 0 205,152 Current operating lease liabilities 0 13,466 Total current liabilities attributable to discontinued operations 18,612 329,347 Deferred revenue long-term 0 2,568 Long-term operating lease liabilities 0 48,068 Other liabilities 0 270 Total long-term liabilities attributable to discontinued operations $ 0 $ 50,906 The following table summarizes the major income and expense line items of the Hospitals and Large Physician Practices Business as reported in the consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021. The activity during the three months ended September 30, 2022 relates to certain adjustments made in connection with the sale of the Hospitals and Large Physician Practices Business, primarily relating to net working capital adjustments that impacted the gain on the sale of the discontinued operations. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Major income and expense line items related to Hospitals and Large Physician Practices: Revenue: Provider $ ( 8 ) $ 224,605 $ 284,791 $ 691,813 Total revenue ( 8 ) 224,605 284,791 691,813 Cost of revenue: Provider 32 145,487 189,530 442,234 Total cost of revenue 32 145,487 189,530 442,234 Gross (loss) profit ( 40 ) 79,118 95,261 249,579 Selling, general and administrative expenses 369 51,384 68,900 151,895 Research and development 25 24,498 32,011 83,288 Asset impairment charges 0 6,160 0 11,232 Amortization of intangible assets 0 3,455 3,538 10,376 Loss from discontinued operations for Hospitals and Large Physician Practices ( 434 ) ( 6,379 ) ( 9,188 ) ( 7,212 ) Other income, net 0 206 12 674 Gain on sale of discontinued operations 5,174 0 7,939 0 Equity in net (loss) income of unconsolidated investments 0 0 ( 76 ) 0 Income (loss) from discontinued operations for Hospitals and Large Physician Practices before income taxes 4,740 ( 6,173 ) ( 1,313 ) ( 6,538 ) Income tax (provision) benefit ( 1,137 ) 2,091 ( 57,986 ) 2,511 Income (loss) from discontinued operations, net of tax for Hospitals and Large Physician Practices $ 3,603 $ ( 4,082 ) $ ( 59,299 ) $ ( 4,027 )
EPSi and CarePort [Member]
Summary of Discontinued Operations in Financial Statements	The following table summarizes the major income and expense line items of EPSi and CarePort as reported in the consolidated statements of operations for the three and nine months ended September 30, 2021. The activity during the three and nine months ended September 30, 2021 relates to certain adjustments made in connection with the sale of EPSi and CarePort, primarily relating to net working capital adjustments that impacted the gain on the sale of the discontinued operations. Three Months Ended Nine Months Ended (In thousands) September 30, 2021 September 30, 2021 Major income and expense line items related to EPSi and CarePort: Revenue: Provider $ 6 $ 6 Total revenue 6 6 Cost of revenue: Provider 19 ( 29 ) Total cost of revenue 19 ( 29 ) Gross (loss) profit ( 13 ) 35 Selling, general and administrative expenses 2 76 Research and development 0 ( 32 ) Loss from discontinued operations for EPSi and CarePort ( 15 ) ( 9 ) Other income, net 1 2 Gain on sale of discontinued operations 0 647 (Loss) income from discontinued operations for EPSi and CarePort before income taxes ( 14 ) 640 Income tax provision 0 ( 169 ) (Loss) income from discontinued operations, net of tax for EPSi and CarePort $ ( 14 ) $ 471

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Our chief operating decision maker uses segment revenues, gross profit and income (loss) from operations as measures of performance and to make decisions about the allocation of resources. We do not track our assets by segment. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2022 2021 2022 2021 Revenue: Veradigm $ 145,391 $ 137,169 $ 426,306 $ 396,988 Unallocated Amounts 6,531 7,499 19,186 22,538 Total revenue $ 151,922 $ 144,668 $ 445,492 $ 419,526 Gross profit: Veradigm $ 78,801 $ 65,696 $ 223,405 $ 187,960 Unallocated Amounts 4,635 3,944 12,994 13,016 Total gross profit $ 83,436 $ 69,640 $ 236,399 $ 200,976 Income (loss) from operations: Veradigm $ 27,707 $ 17,099 $ 69,796 $ 46,607 Unallocated Amounts ( 2,706 ) 1,385 ( 43,579 ) ( 3,576 ) Total income (loss) from operations $ 25,001 $ 18,484 $ 26,217 $ 43,031

Supplemental Disclosures (Table

Supplemental Disclosures (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Disclosures	The majority of the restricted cash balance as of September 30, 2022 and 2021 represents lease deposits. September 30, (In thousands) 2022 2021 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 492,597 $ 142,333 Restricted cash 1,307 1,307 Total cash, cash equivalents and restricted cash $ 493,904 $ 143,640 Nine Months Ended September 30, (In thousands) 2022 2021 Supplemental non-cash information: Sale of 2bPrecise business in exchange for a non-controlling interest in the combined entity $ 0 $ 11,768 Issuance of treasury stock to commercial partner $ 0 $ 534

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Jan. 01, 2022	Dec. 31, 2021
Basis Of Presentation And Significant Accounting Policies [Line Items]
Long-term Debt		$ 26,400
Additional paid-in capital		38,900
Retained earnings	$ 753,392	$ 12,500	$ 767,556
Accounting Standards Update 2020-06 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2022
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Additional Information (Detail) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) Revenue_Stream	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Disaggregation of Revenue [Line Items]
Number of primary revenue streams | Revenue_Stream			2
Total unsatisfied performance obligations	$ 989		$ 989
Total unsatisfied performance obligations, percentage, year one	41%		41%
Total unsatisfied performance obligations, percentage after year one	59%		59%
Selling, General and Administrative Expenses [Member]
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost Amortization	$ 3	$ 3.1	$ 8.8	$ 9.3
Prepaid Expenses and Other Current Assets [Member]
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost, Gross	9.4		9.4		$ 8.1
Other Assets [Member]
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost, Gross	$ 10.6		$ 10.6		$ 11.9

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue related to deferred revenue balance at beginning of period	$ 22,450	$ 25,901	$ 36,151	$ 38,801	$ 36,770	$ 29,401
Revenue related to new performance obligations satisfied during the period	59,228	55,990	45,306	41,013	41,814	47,263
Revenue recognized under "right-to-invoice" expedient	70,127	68,877	61,114	64,531	62,105	56,811
Reimbursed travel expenses, shipping and other revenue	117	130	101	323	517	177
Total revenue	$ 151,922	$ 150,898	$ 142,672	$ 144,668	$ 141,206	$ 133,652	$ 445,492	$ 419,526

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Total revenue	$ 151,922	$ 150,898	$ 142,672	$ 144,668	$ 141,206	$ 133,652	$ 445,492	$ 419,526
Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6,531			7,499			19,186	22,538
Veradigm [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	145,391			137,169			426,306	396,988
Veradigm [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	145,391			137,169			426,306	396,988
Provider [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	122,811			118,179			360,415	345,253
Provider [Member] | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6,531			7,499			19,186	22,538
Provider [Member] | Veradigm [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	116,280			110,680			341,229	322,715
Payer & Life Sciences
Disaggregation Of Revenue [Line Items]
Total revenue	29,111			26,489			85,077	74,273
Payer & Life Sciences | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	0			0			0	0
Payer & Life Sciences | Veradigm [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 29,111			$ 26,489			$ 85,077	$ 74,273

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Summary of Changes in Estimate of Credit Losses for Contract Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Beginning Balance	$ 2,110	$ 2,110
Write-offs	(345)	0
Ending balance	1,765	2,110
Less: Contract assets, short-term	564	576	$ 576
Total contract assets, long-term	$ 1,201	$ 1,534	$ 1,534

Accounts Receivable - Schedule

Accounts Receivable - Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable (Detail) - Trade Accounts Receivable [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Accounts Notes And Loans Receivable [Line Items]
Beginning Balance	$ 13,360	$ 20,228
Current period provision	1,979	1,432
Write-offs	(2,471)	(2,291)
Ending Balance	$ 12,868	$ 19,369

Leases - Additional Information

Leases - Additional Information (Detail) - Maximum [Member]	9 Months Ended
	Sep. 30, 2022
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	5 years
Operating leases, options to extend leases term	5 years
Operating leases, options to terminate leases term	1 year

Leases - Summary of Operating C

Leases - Summary of Operating Costs Associated with Leased Assets (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease cost	[1]	$ 1,466	$ 1,828	$ 4,681	$ 5,652
Less: Sublease income		(98)	(61)	(196)	(218)
Total operating lease costs		$ 1,368	$ 1,767	$ 4,485	$ 5,434
[1] Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information for Operating Leases (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating cash flows from operating leases	$ 5,213	$ 5,615
Right-of-use assets obtained in exchange for operating lease obligations	$ 273	$ 0

Leases - Summary of Balance She

Leases - Summary of Balance Sheet Location and Balances for Operating Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Right-of-use assets - operating leases	$ 14,520	$ 18,324
Current operating lease liabilities	6,166	6,133
Long-term operating lease liabilities	$ 12,315	$ 16,754
Weighted average remaining lease term (in years)	4 years	5 years
Weighted average discount rate	3.30%	3.40%

Leases - Summary of Future Matu

Leases - Summary of Future Maturities of Lease and Non-Lease Components (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Operating Leases [Abstract]
Operating Leases, Remainder of 2022	$ 1,666
Operating Leases, 2023	6,421
Operating Leases, 2024	3,706
Operating Leases, 2025	3,453
Operating Leases, 2026	2,835
Operating Leases, Thereafter	1,581
Operating Leases, Total lease liabilities	19,662
Operating Leases, Less: Amount representing interest	(1,181)
Operating Leases, Less: Short-term lease liabilities	(6,166)	$ (6,133)
Operating Leases, Total Long-term lease liabilities	$ 12,315	$ 16,754

Business Combinations and Div_3

Business Combinations and Divestitures - Additional Information (Detail) - USD ($) $ in Thousands						3 Months Ended			9 Months Ended		12 Months Ended
	May 02, 2022	Mar. 25, 2022	Aug. 23, 2021	Dec. 31, 2020	Oct. 15, 2020	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Business combination, acquisition related costs									$ 200
Pre-tax gain (loss) on sale of business						$ 0		$ 8,363	0	$ 8,363
Cash		$ 24,500
Purchase price in cash		24,000
Intangible assets						7,280			7,280
Goodwill						523,927			523,927		$ 506,607
Deferred taxes, net						$ 8,082			8,082		16,625
2bPrecise [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business			$ 8,400
CarePort Purchase Agreement [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business											$ 600
CarePort Purchase Agreement [Member] | WellSky Corp [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business				$ 933,900
Sale of business unit				$ 1,350,000
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business					$ 222,600
Sale of business unit					$ 365,000
Hospitals and Large Physician Practices business [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business									$ 7,900
Babel Health [Member]
Business Acquisition [Line Items]
Total consideration for Babel Health		$ 24,000
Harris Dawn Holdings Inc. [Member]
Business Acquisition [Line Items]
Sale of business unit	$ 670,000
Additional cash	$ 30,000
American College of Cardiology [Member]
Business Acquisition [Line Items]
Date of acquisition							Mar. 25, 2022

Business Combinations and Div_4

Business Combinations and Divestitures - Schedule of Assets Acquired and Liabilities Assumed (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Business Combinations [Abstract]
Cash and cash equivalents	$ 472
Accounts receivable, net	394
Prepaid expenses and other current assets	206
Fixed assets	48
Intangible assets	7,280
Goodwill	17,320
Other assets	217
Accounts payable and accrued expenses	(752)
Deferred revenue	(675)
Net assets acquired	$ 24,510

Business Combinations and Div_5

Business Combinations and Divestitures - Schedule of Acquired Intangible Assets Amortization (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 7,280
Trade Names [Member]
Business Acquisition [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	1 year
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 40
Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	21 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 4,640
Technology [Member]
Business Acquisition [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 2,600

Fair Value Measurements and L_3

Fair Value Measurements and Long-term Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 74,384	$ 60,511
Total assets	0	352
Total liabilities	70	19
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	352
Total liabilities	70	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	19
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	352
Accrued expenses	70	0
Foreign exchange derivative assets [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Accrued expenses	0	0
Foreign exchange derivative assets [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	352
Accrued expenses	70	0
Foreign exchange derivative assets [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Accrued expenses	0	0
Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	19
Contingent Consideration Current [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Contingent Consideration Current [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Contingent Consideration Current [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	$ 0	$ 19

Fair Value Measurements and L_4

Fair Value Measurements and Long-term Investments - Summary of Changes in Liability Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Inputs, Level 3 [Member] - Contingent Consideration [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2021	$ 19
Payments	(19)
Balance at September 30, 2022	$ 0

Fair Value Measurements and L_5

Fair Value Measurements and Long-term Investments - Summary of Long-term Equity Investments Included in Other Assets (Detail) $ in Thousands		9 Months Ended
		Sep. 30, 2022 USD ($) Investment	Dec. 31, 2021 USD ($)
Fair Value Disclosures [Abstract]
Equity method investments, Number of Investees | Investment	[1]	5
Cost with adjustments, Number of investees | Investment		7
Total long-term equity investments, Number of Investees | Investment		12
Equity method investments, Original Cost	[1]	$ 8,190
Cost with adjustments, Original Cost		47,114
Total long-term equity investments, Original Cost		55,304
Equity method investments, Carrying Value	[1]	12,053	$ 12,260
Cost with adjustments, Carrying Value		49,099	49,293
Total long-term equity investments, Carrying Value		$ 61,152	$ 61,553
[1] Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and L_6

Fair Value Measurements and Long-term Investments - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment of long-term investments	$ 0
Gain on Sale of Businesses, Net [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Gain on sale of businesses		$ 8,400
Third-party Cost Method Investments [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Conversion of notes into shares		475
Third-party Cost Method Investments [Member] | Other Income (Loss), Net [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Gain on note conversion and revaluation of existing investment		$ 9,700

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)				3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 24, 2022	May 26, 2021	Nov. 18, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Class Of Stock [Line Items]
Capitalized stock-based compensation costs				$ 0	$ 0	$ 0	$ 0
Stock options granted						0	0
Share issued, exercise of options and release of stock awards						2,900,000		2,200,000
Shares settled for tax withholding						1,600,000	900,000
Common stock repurchased, amount						$ 177,031,000	$ 308,953,000
2020 Stock Purchase Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount							$ 101,500,000
Common stock repurchased, shares						1,600,000	5,600,000
Common stock available to repurchase			$ 300,000,000
2021 Stock Purchase Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount							$ 241,700,000
Common stock repurchased, shares							13,900,000
Common stock available to repurchase		$ 350,000,000
Accelerated Share Repurchases Settlement					$ 38,800		$ 38,800
Previous Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount				33,700,000
Accelerated Share Repurchase Agreement [Member]
Class Of Stock [Line Items]
Shares of common stock yet to be repurchased, amount				$ 73,200,000		$ 73,200,000
Two Thousand Twenty Two Stock Purchase Program
Class Of Stock [Line Items]
Common stock repurchased, amount						$ 177,000,000
Common stock repurchased, shares				1,900,000		9,700,000
Common stock available to repurchase	$ 250,000,000
Accelerated share repurchases stock					2,400

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 4,712	$ 3,172	$ 20,799	$ 10,668
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	329	265	892	867
Cost of revenue [Member] | Provider [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	283	213	821	709
Cost of revenue [Member] | Payer & Life Sciences
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	46	52	71	158
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	3,831	2,079	17,629	6,967
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 552	$ 828	$ 2,278	$ 2,834

Stockholders' Equity - Stock-_2

Stockholders' Equity - Stock-Based Awards Granted (Detail) - $ / shares shares in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	14	1,761
Weighted-Average Grant Date Fair Value, granted	$ 15.82	$ 18.94
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	14	1,260
Weighted-Average Grant Date Fair Value, granted	$ 15.82	$ 18.41
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	243
Weighted-Average Grant Date Fair Value, granted	$ 0	$ 18.56
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	258
Weighted-Average Grant Date Fair Value, granted	$ 0	$ 21.90

Earnings (Loss) Per Share - Cal

Earnings (Loss) Per Share - Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Basic earnings (loss) per Common Share:
Income from continuing operations, net of tax	$ 10,925	$ 20,276	$ 32,658	$ 50,719
Income (loss) from discontinued operations, net of tax	3,603	(4,096)	(59,299)	(3,556)
Net income (loss)	$ 14,528	$ 16,180	$ (26,641)	$ 47,163
Weighted-average common shares outstanding	110,206	123,892	113,419	133,517
Basic earnings from continuing operations per Common Share	$ 0.10	$ 0.16	$ 0.29	$ 0.38
Basic earnings (loss) from discontinued operations per Common Share	0.03	(0.03)	(0.52)	(0.03)
Net earnings (loss) per Common Share	$ 0.13	$ 0.13	$ (0.23)	$ 0.35
Diluted earnings (loss) per Common Share:
Income from continuing operations	$ 10,925	$ 20,276	$ 32,658	$ 50,719
Plus: Interest expense, net of tax, associated with 0.875% Convertible Senior Notes	506	0	1,519	0
Income from continuing operations, net of tax after the effect of assumed conversions	11,431	20,276	34,177	50,719
Income (loss) from discontinued operations, net of tax	$ 3,603	$ (4,096)	$ (59,299)	$ (3,556)
Weighted-average common shares outstanding	110,206	123,892	113,419	133,517
Plus: Dilutive effect of restricted stock unit awards, convertible notes and warrants	18,665	7,460	20,861	8,564
Weighted-average common shares outstanding assuming dilution	128,871	131,352	134,280	142,081
Diluted earnings from continuing operations per Common Share	$ 0.09	$ 0.15	$ 0.25	$ 0.36
Diluted (loss) earnings from discontinued operations per Common Share	0.03	(0.03)	(0.44)	(0.03)
Net earnings (loss) per Common Share	$ 0.12	$ 0.12	$ (0.19)	$ 0.33

Earnings (Loss) Per Share - Ant

Earnings (Loss) Per Share - Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Shares subject to anti-dilutive restricted stock unit awards and warrants excluded from calculation	1,452	1,504	180	1,502

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 654,208	$ 646,928
Accumulated Amortization	(560,953)	(549,238)
Intangible Assets, Net	93,255	97,690
Registered trademarks	52,000	52,000
Goodwill	523,927	506,607
Total	575,927	558,607
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	252,083	249,483
Accumulated Amortization	(232,475)	(227,408)
Intangible Assets, Net	19,608	22,075
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	402,125	397,445
Accumulated Amortization	(328,478)	(321,830)
Intangible Assets, Net	$ 73,647	$ 75,615

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill [Line Items]
Goodwill	$ 506,607
Additions	17,320
Goodwill	523,927
Veradigm [Member] | Operating Segments [Member]
Goodwill [Line Items]
Goodwill	467,630
Additions	17,320
Goodwill	484,950
Unallocated [Member] | Operating Segments [Member]
Goodwill [Line Items]
Goodwill	38,977
Additions	0
Goodwill	$ 38,977

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 0	$ 0

Debt - Debt Outstanding Excludi

Debt - Debt Outstanding Excluding Lease Obligations (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument principal amount	$ 207,911	$ 342,853
Unamortized Discount and Debt Issuance Costs	7,585	(7,209)
Net Carrying Amount	200,326	350,062
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	207,911	167,853
Unamortized Discount and Debt Issuance Costs	3,875	(9,057)
Net Carrying Amount	204,036	176,910
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	0	175,000
Unamortized Discount and Debt Issuance Costs	3,710	1,848
Net Carrying Amount	$ (3,710)	$ 173,152

Debt - Debt Outstanding Exclu_2

Debt - Debt Outstanding Excluding Lease Obligations (Parenthetical) (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Jan. 01, 2022	Dec. 31, 2021	Dec. 31, 2019
Debt Instrument [Line Items]
Long-Term Debt, Gross	$ 207,911		$ 342,853
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	207,900		207,911	$ 218,000
Long-Term Debt, Gross	$ 207,911		167,853
Additional Paid-In Capital [Member] | 0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Carrying Amount of Equity Component		$ 40,100	$ 40,058	$ 40,100

Debt - Interest Expense (Detail

Debt - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Total interest expense	$ 1,246	$ 3,617	$ 5,269	$ 9,709
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense	816	1,742	3,406	4,109
Amortization of discounts and debt issuance costs	430	1,875	1,863	5,600
Total interest expense	$ 1,246	$ 3,617	$ 5,269	$ 9,709

Debt - Interest Expense Related

Debt - Interest Expense Related to 0.875% Convertible Senior Notes (Detail) - 0.875% Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Coupon interest	$ 454	$ 454	$ 1,364	$ 1,364
Amortization of discounts and debt issuance costs	228	1,479	684	4,412
Total interest expense related to the 0.875% Convertible Senior Notes	$ 682	$ 1,933	$ 2,048	$ 5,776

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended
	Jan. 01, 2022	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2022	Jun. 30, 2022	Apr. 29, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument principal amount				$ 207,911			$ 342,853
Additional paid-in capital	$ 38,900
Long term debt	26,400
Retained Earnings (Accumulated Deficit)	12,500			753,392			767,556
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount				0			175,000
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount				207,911			167,853
Debt instrument principal amount			$ 218,000	$ 207,900			207,911
Additional paid-in capital	38,900
Long term debt	26,400
Interest rate		0.875%	0.875%	0.875%	0.875%
Debt issuance costs			$ 700
Percentage of interest rate used to to compute the initial fair value of the liability component			1.95%
Debt instrument, initial fair value of liability component			$ 177,900
Retained Earnings (Accumulated Deficit)	12,500
Debt instrument, net carrying value of equity component				$ 16,400
Payments for repurchase debt instrument		$ 7,700
Debt instrument aggregate principal amount repurchased		10,100
Gain on repurchase of debt instrument		500
Proceeds due to termination of capped call transaction		300
Reduction to capped call fees		800
Loss in capped call		$ 500
0.875% Convertible Senior Notes [Member] | Additional Paid-In Capital [Member]
Debt Instrument [Line Items]
Debt instrument, equity component amount	40,100		40,100				$ 40,058
Payments of capped call fees			17,200
Debt discounts and issuance costs	$ 1,100		$ 1,100
Revolving credit facility [Member]
Debt Instrument [Line Items]
Available for the issuance of letters of credit						$ 50,000
Borrowing Capacity						700,000
Available for swingline loans						25,000
Credit facility borrowed under certain foreign currencies						$ 100,000
Letters of credit outstanding				800
Credit facility, amount available borrowing capacity				$ 699,200

Debt - Summary of Future Debt P

Debt - Summary of Future Debt Payment Obligations (Detail) $ in Thousands	Sep. 30, 2022 USD ($)
Debt Instrument [Line Items]
Total	$ 207,911
2022	0
2023	0
2024	0
2025	0
2026	0
Thereafter	207,911
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total	207,911	[1]
2022	0	[1]
2023	0	[1]
2024	0	[1]
2025	0	[1]
2026	0	[1]
Thereafter	$ 207,911	[1]
[1] Amount represents the face value of the 0.875 % Convertible Senior Notes.

Debt - Summary of Future Debt_2

Debt - Summary of Future Debt Payment Obligations (Parenthetical) (Detail)	Sep. 30, 2022	Jun. 30, 2022	Jun. 30, 2020	Dec. 31, 2019
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate	0.875%	0.875%	0.875%	0.875%

Income Taxes - Effective Tax Ra

Income Taxes - Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income from continuing operations before income taxes	$ 24,793	$ 27,466	$ 23,526	$ 63,183
Income tax (provision) benefit	$ (13,868)	$ (7,190)	$ 9,132	$ (12,464)
Effective tax rate	55.90%	26.20%	38.80%	19.70%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Windfall benefit			$ 12.6	$ 4.6
Pretax income (loss)	$ 24.8	$ 27.5	$ (23.5)	$ 63.2
Cumulative operating income loss period considered			3 years
Valuation allowance	11.2		$ 11.2
Unrecognized income tax benefits	$ 31.7		31.7		$ 30.3
Domestic Deferred Tax Assets [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance			$ 11.2

Derivative Financial Instrume_3

Derivative Financial Instruments - Fair Value and Balance Sheet Locations (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 0	$ 352
Derivative liability, fair value	70	0
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	0	352
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 70	$ 0

Derivative Financial Instrume_4

Derivative Financial Instruments - Additional Information (Detail) - Foreign Exchange Forward Contracts [Member] ₨ in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2022 INR (₨) Number	Sep. 30, 2022 USD ($) Number
Derivative [Line Items]
Number of contracts | Number	3	3
Derivative notional amount outstanding	₨ 50	$ 0.6
Foreign Currency Cash Flow Gain Loss To Be Reclassified During Specified Period | $		$ 0.1
Estimated period of unrealized losses included in AOCI reclassified into income	12 months
Maximum [Member]
Derivative [Line Items]
Date of contracts mature	Dec. 31, 2022
Minimum [Member]
Derivative [Line Items]
Date of contracts mature	Oct. 31, 2022

Derivative Financial Instrume_5

Derivative Financial Instruments - Derivatives Instruments Designated as Cash Flow Hedges (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI	$ (76)	$ 0	$ (379)	$ 121
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	(21)	0	15	611
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	(14)	0	9	351
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	$ (25)	$ 0	$ 17	$ 668

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2022		Sep. 30, 2021	Sep. 30, 2022		Sep. 30, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period				$ 1,408,138
Other comprehensive (loss) income before reclassifications				(1,090)		$ (195)
Net (gains) losses reclassified from accumulated other comprehensive loss				(31)		(1,209)
Total other comprehensive income (loss)	$ 48		$ (805)	(1,121)		(1,404)
Balance at the end of the period	1,177,023			1,177,023
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period				(3,026)	[1]	(2,957)	[2]
Other comprehensive (loss) income before reclassifications				(808)		(285)
Net (gains) losses reclassified from accumulated other comprehensive loss				0		0
Total other comprehensive income (loss)				(808)		(285)
Balance at the end of the period	(3,834)	[3]	(3,242)	(3,834)	[3]	(3,242)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period				261	[1]	1,119	[2]
Other comprehensive (loss) income before reclassifications				(282)		90
Net (gains) losses reclassified from accumulated other comprehensive loss				(31)		(1,209)
Total other comprehensive income (loss)				(313)		(1,119)
Balance at the end of the period	(52)	[3]	0	(52)	[3]	0
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period				(2,765)	[1]	(1,838)	[2]
Balance at the end of the period	$ (3,886)	[3]	$ (3,242)	$ (3,886)	[3]	$ (3,242)
[1] Net of taxes of $ 91 thousand for unrealized net gains on foreign exchange contract derivatives. Net of taxes of $ 390 thousand for unrealized net gains on foreign exchange contract derivatives. Net of taxes of $ 18 thousand for unrealized net losses on foreign exchange contract derivatives.

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Revaluation of tax effects	$ 18	$ 91	$ 390

Accumulated Other Comprehensi_5

Accumulated Other Comprehensive Loss - Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 59	$ (805)	$ (808)	$ (285)
Foreign currency translation adjustments, Tax Effect	0	0	0	0
Foreign currency translation adjustments, Net	59	(805)	(808)	285
Other comprehensive income (loss) before income tax benefit	43	(805)	(1,228)	(1,794)
Other comprehensive income (loss), Tax effect	5	0	107	390
Total other comprehensive income (loss)	48	(805)	(1,121)	(1,404)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Before-Tax, Amount	(76)	0	(379)	121
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	20	0	97	(31)
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	(56)	0	(282)	90
Derivatives qualifying as cash flow hedges, net losses (gains) reclassified into income, Before-Tax Amount	60	0	(41)	(1,630)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	(15)	0	10	421
Derivatives qualifying as cash flow hedges, net losses (gains) reclassified into income, Net	45	0	(31)	(1,209)
Derivatives qualifying as cash flow hedges, net change in unrealized (losses) gains on foreign exchange contracts, Before-Tax Amount, Total	(16)	0	(420)	(1,509)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	5	0	107	390
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent, Total	$ (11)	$ 0	(313)	(1,119)
Total other comprehensive income (loss)			$ (313)	$ (1,119)

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Practice Fusion, Inc. [Member] - USD ($)			12 Months Ended
	Apr. 05, 2022	Mar. 18, 2022	Dec. 31, 2020
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 200,000,000
Deferred Prosecution Agreement [Member]
Loss Contingencies [Line Items]
Increase (Decrease) in Other Deferred Liability		$ 200,000
Criminal Fine [Member] | US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			$ 25,300,000
Forfeiture Payment [Member] | US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			959,700
Civil Settlements [Member] | US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			118,600,000
State Medicaid Program Expenditures [Member] | US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			$ 5,200,000

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2022 Segment Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of reportable segments | Segment	2
EPSi and CarePort [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of businesses sold | Business	2

Discontinued Operations - Summa

Discontinued Operations - Summary of Major Classes of Assets and Liabilities as Reported on Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Cash and cash equivalents	$ 492,597	$ 132,517	$ 142,333
Total current assets attributable to discontinued operations	8,000	331,955
Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Total current liabilities attributable to discontinued operations	18,612	329,347
Hospitals and Large Physician Practice [Member]
Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Cash and cash equivalents	8,000	55,834
Restricted Cash	0	861
Accounts receivable, net of allowance of $16,584 as of December 31, 2021	0	155,447
Contract assets, net of allowance of $492 as of December 31, 2021	0	61,382
Prepaid expenses and other current assets	0	58,431
Total current assets attributable to discontinued operations	8,000	331,955
Fixed assets, net	0	38,083
Software development costs, net	0	97,416
Intangible assets, net	0	86,240
Goodwill	0	467,871
Deferred taxes, net	0	6,607
Contract assets - long-term, net of allowance of $739 as of December 31, 2021	0	28,623
Right-of-use assets - operating leases	0	50,585
Other assets	0	17,731
Total long-term assets attributable to discontinued operations	0	793,156
Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Accounts payable	17,687	11,555
Accrued expenses	0	38,007
Income tax payable	925	0
Accrued compensation and benefits	0	61,167
Deferred revenue	0	205,152
Current operating lease liabilities	0	13,466
Total current liabilities attributable to discontinued operations	18,612	329,347
Deferred revenue long-term	0	2,568
Long-term operating lease liabilities	0	48,068
Other liabilities	0	270
Total long-term liabilities attributable to discontinued operations	$ 0	$ 50,906

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Major Classes of Assets and Liabilities as Reported on Consolidated Balance Sheets (Parenthetical) (Detail) - Hospital And Large Physician Practices [Member] $ in Thousands	Dec. 31, 2021 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group including discontinued operation accounts receivable, allowance	$ 16,584
Disposal group including discontinued operation contract asset, allowance current	492
Disposal group including discontinued operation contract asset - long term, allowance	$ 739

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Major Income and Expense Line Items Reported in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Cost of revenue:
Asset impairment charges	$ 0	$ 359	$ 0	$ 531
Gain on sale of discontinued operations	5,174	0	7,939	647
Equity in net loss income of unconsolidated investments	(617)	(257)	(1,222)	(321)
Income (loss) from discontinued operations before income taxes	(434)	(6,187)	(9,252)	(6,545)
Income tax (provision) benefit	(1,137)	2,091	(57,986)	2,342
Income (loss) from discontinued operations, net of tax	3,603	(4,096)	(59,299)	(3,556)
Hospital And Large Physician Practices [Member]
Revenue:
Total revenue	(8)	224,605	284,791	691,813
Cost of revenue:
Total cost of revenue	32	145,487	189,530	442,234
Gross (loss) profit	(40)	79,118	95,261	249,579
Selling, general and administrative expenses	369	51,384	68,900	151,895
Research and development	25	24,498	32,011	83,288
Asset impairment charges	0	6,160	0	11,232
Amortization of intangible assets	0	3,455	3,538	10,376
Loss from discontinued operations	(434)	(6,379)	(9,188)	(7,212)
Other income, net	0	206	12	674
Gain on sale of discontinued operations	5,174	0	7,939	0
Equity in net loss income of unconsolidated investments	0	0	(76)	0
Income (loss) from discontinued operations before income taxes	4,740	(6,173)	(1,313)	(6,538)
Income tax (provision) benefit	(1,137)	2,091	(57,986)	2,511
Income (loss) from discontinued operations, net of tax	3,603	(4,082)	(59,299)	(4,027)
EPSi and CarePort [Member]
Revenue:
Total revenue		6		6
Cost of revenue:
Total cost of revenue		19		(29)
Gross (loss) profit		(13)		35
Selling, general and administrative expenses		2		76
Research and development		0		(32)
Loss from discontinued operations		(15)		(9)
Other income, net		1		2
Gain on sale of discontinued operations		0		647
Income (loss) from discontinued operations before income taxes		(14)		640
Income tax (provision) benefit		0		(169)
Income (loss) from discontinued operations, net of tax		(14)		471
Provider [Member] | Hospital And Large Physician Practices [Member]
Revenue:
Total revenue	(8)	224,605	284,791	691,813
Cost of revenue:
Total cost of revenue	$ 32	145,487	$ 189,530	442,234
Provider [Member] | EPSi and CarePort [Member]
Revenue:
Total revenue		6		6
Cost of revenue:
Total cost of revenue		$ 19		$ (29)

Business Segments - Additional

Business Segments - Additional Information (Detail)		9 Months Ended
	Jan. 01, 2022 Segment	Sep. 30, 2022 Segment Revenue_Stream
Segment Reporting [Abstract]
Number of primary revenue streams | Revenue_Stream		2
Number of operating segments	3
Number of reportable segments		2

Business Segments - Revenues an

Business Segments - Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 151,922	$ 150,898	$ 142,672	$ 144,668	$ 141,206	$ 133,652	$ 445,492	$ 419,526
Gross profit	83,436			69,640			236,399	200,976
Income (loss) from operations	25,001			18,484			26,217	43,031
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	6,531			7,499			19,186	22,538
Gross profit	4,635			3,944			12,994	13,016
Income (loss) from operations	(2,706)			1,385			(43,579)	(3,576)
Veradigm [Member]
Segment Reporting Information [Line Items]
Revenue	145,391			137,169			426,306	396,988
Gross profit	78,801			65,696			223,405	187,960
Income (loss) from operations	$ 27,707			$ 17,099			$ 69,796	$ 46,607

Supplemental Disclosures - Supp

Supplemental Disclosures - Supplemental Disclosures (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 492,597	$ 142,333	$ 132,517
Restricted cash	1,307	1,307	$ 1,308
Total cash, cash equivalents and restricted cash	493,904	143,640
Supplemental non-cash information:
Issuance of treasury stock to commercial partner	0	534
2bPrecise [Member]
Supplemental non-cash information:
Sale of 2bPrecise business in exchange for a non-controlling interest in the combined entity	$ 0	$ 11,768